

08/03/98
JCS556 U.S. PTO

LIMBACH & LIMBACH L.L.P.
2001 Ferry Building, San Francisco, CA 94111
415/433-4150

Address to:

Box Patent Application

Assistant Commissioner for Patents

Washington, D.C. 20231

Attorney's Docket No. CRDP-2700

[CPC2000.004]

First Named Inventor N. PARKER WILLIS, et al.

UTILITY PATENT APPLICATION TRANSMITTAL
(under 37 CFR 1.53(b))

SIR:

Transmitted herewith for filing is the patent application entitled:

**A DYNAMICALLY ALTERABLE THREE-DIMENSIONAL GRAPHICAL MODEL OF A
BODY REGION**

CERTIFICATION UNDER 37 CFR § 1.10

I hereby certify that this New Application and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date August 3, 1998, in an envelope bearing "Express Mail Post Office To Addressee" Mailing Label Number EM503277091US addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

SUSAN OZANNE
(Name of person mailing paper)

Susan Ozanne
(Signature)

Enclosed are:

- I. ☒ Transmittal Form (two copies required)
- II. The papers required for filing date under CFR § 1.53(b):
 - i. 79 Pages of specification (including claims and abstract);
 - ii. 40 Sheets of drawings.
☐ formal ☒ informal
- III. Declaration or oath
 - a. ☒ Newly executed (original or copy)
- IV. ☐ Microfiche Computer Program (Appendix, see 37 CFR 1.96)
- V. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - i. ☐ Computer Readable Copy
 - ii. ☐ Paper Copy (identical to computer copy)
 - iii. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- VI. ☒ An assignment of the invention to Cardiac Pathways Corporation is attached (including Form PTO-1595).
 - i. ☒ 37 CFR 3.73(b) Statement (when there is an assignee)
- VII. ☒ Power of Attorney
- VIII. ☐ An Information Disclosure Statement (IDS) is enclosed, including a PTO-1449 and copies of ☐ references.

JCS556 U.S. PTO
09/128304
08/03/98

09/128304-080398

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

- Abstract**

Abstract

Abstract

[illegible]

Abstract

Abstract

Abstract

Abstract

Abstract

[illegible]

- Abstract**

Abstract

Abstract

Abstract

Abstract

- [illegible]

XVII. All correspondence regarding this application should be forwarded to the undersigned attorney:

Kathleen A. Frost
Limbach & Limbach L.L.P.
2001 Ferry Building
San Francisco, CA 94111
Telephone: 415/433-4150
Facsimile: 415/433-8716

XVIII. Authorization to Charge Additional Fees

X The Commissioner is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR § 1.16 or § 1.17 to Account No. 12-1420. A duplicate of this transmittal is attached.

LIMBACH & LIMBACH L.L.P.

August 3, 1998
(Date)

Attorney Docket No. CRDP-2700
[CPC2000.004]

By: Kathleen A. Frost
Kathleen A. Frost
Registration No. 37,326
Attorney(s) or Agent(s) of Record

A DYNAMICALLY ALTERABLE THREE-DIMENSIONAL
GRAPHICAL MODEL OF A BODY REGION

Inventors: N. Parker Willis, Jinglin Zeng, James A. Quarato

Field Of The Invention

5 The present invention relates to a system for creating a three-
dimensional graphical model of a region within a living body and for
dynamically altering the graphical model to increase its conformity
with the actual region in the patient's body using physical
characteristics acquired from a medical device probing the region of
10 interest.

Background Of The Invention

15 For certain types of minimally invasive medical procedures,
endoscopic visualization of the treatment site within the body is
unavailable or does not assist the clinician in guiding the needed
medical devices to the treatment site.

20 Examples of such procedures are those used to diagnose and
treat supra-ventricular tachycardia (SVT), atrial fibrillation (AF), atrial
flutter (AFL) and ventricular tachycardia (VT). SVT, AFL, AF and VT
are conditions in the heart which cause abnormal electrical signals to
be generated in the endocardial tissue to cause irregular beating of
the heart.

25 A procedure for diagnosing and treating SVT or VT involves
measuring the electrical activity of the heart using an
electrophysiology catheter introduced into the heart via the patient's
vasculature. The catheter carries mapping electrodes which are

PATENT APPLICATION

Express Mailing Label: EM503277091US

positioned within the heart and used to measure electrical activity. The position of the catheter within the heart is ascertained using fluoroscopic images. A map of the measured activity is created based on the fluoroscopic images and is shown on a graphical display. A physician uses the map to identify the region of the endocardium which s/he believes to be the source of the abnormal electrical activity. An ablation catheter is then inserted through the patient's vasculature and into the heart where it is used to ablate the region identified by the physician.

To treat atrial fibrillation (AF), an ablation catheter is maneuvered into the right or left atrium where it is used to create elongated ablation lesions in the heart. These lesions are intended to stop the irregular beating of the heart by creating non-conductive barriers between regions of the atria. These barriers halt passage through the heart of the abnormal electrical activity generated by the endocardium. Following the ablation procedure, a mapping catheter is positioned in the heart where it is used to measure the electrical activity within the atria so that the physician may evaluate whether additional lesions are needed to form a sufficient line of block against passage of abnormal currents. S/he may also attempt to induce atrial fibrillation using a pacing electrode, and then further evaluate the line of block by analyzing the time required for the induced electrical activity to pass from one side of the block to the other.

The procedures used to diagnose and treat SVT, VT, AFL and AF utilize catheters which are maneuvered within the heart under fluoroscopy. Because the fluoroscopic image is in two-dimensions and has fairly poor resolution, it may be difficult for the physician to be certain of the catheter positions. Thus, for example, once a

PATENT APPLICATION

Express Mailing Label: EM503277091US

physician has identified an area which is to be ablated (using a map of the measured electrical activity of the heart) it may be difficult to navigate an ablation catheter to the appropriate location in order to accurately ablate the area of concern. It is therefore desirable to provide a system by which the positions of medical devices such as mapping and ablation catheters may be accurately guided to selected regions of the body.

Co-pending U.S. Application No. 08/905,090, filed August 1, 1997, entitled SYSTEM FOR ELECTRODE LOCALIZATION USING ULTRASOUND, assigned to Cardiac Pathways Corporation and incorporated herein by reference, describes a device localization system that uses one or more ultrasound reference catheters to establish a fixed three-dimensional coordinate system within a patient's heart, preferably using principles of triangulation. The coordinate system is represented graphically in three-dimensions on a video monitor and aids the clinician in guiding other medical devices, which also carry ultrasound transducers, through the body to locations at which they are needed to perform clinical procedures. The system is preferably used in the heart to help the physician guide mapping catheters for measuring electrical activity, and ablation catheters for ablating selected regions of cardiac tissue, to desired locations within the heart.

Three-dimensional images are shown on a video display which represent the three-dimensional positions and orientations of the medical devices used with the system, such as the reference catheters, and the electrodes of the mapping catheter and ablation catheter. The video display may additionally include representations (color differences, isopotential or isochronal maps, symbols etc.) of the electrical activity measured by each mapping electrode at its

PATENT APPLICATION

Express Mailing Label: EM503277091US

respective location on the three-dimensional display. It may also represent ablation lesions formed within the body at the appropriate three-dimensional locations, and/or certain anatomic structures which may facilitate navigation of the medical device(s) within the patient.

An enhancement to the three-dimensional localization system described above has now been developed. The enhancement improves the graphical display by showing medical devices positioned within the living body superimposed with a three-dimensional graphical representation of the region of interest within the patient's body. The graphical representation of the region of interest is based upon a model of the region of interest programmed into the system software and dynamically updated to conform with the actual region of interest as information concerning actual features of the region of interest is gathered using a probe manipulated within the patient's body.

Summary Of The Invention

The present invention is a system and method for graphically displaying a three-dimensional model of a region located within a living body. A three-dimensional model of a region of interest is generated for display on a graphical display. The location in three-dimensional space of a physical characteristic (e.g. a structure, wall or space) in the region of interest is determined using at least one probe positioned within the living body. The model is deformed to approximately reflect the determined three-dimensional location of the physical characteristic and the model as deformed is displayed. Preferably, the probe or probes are moved throughout the region of interest so as to gather multiple data points that can be used to

increase the conformity between the model and the actual region of interest within the patient.

Brief Description Of The Drawings

Fig. 1 is a schematic representation of a model transformation system according to the invention in combination with a localization system useful in connection with the invention, showing the major components of the systems.

Figs. 2 through 36C illustrate features of a localization system which may be used in connection with a model transformation system according to the present invention, in which:

Fig. 2 is a schematic representation of a three-dimensional coordinate system established using a reference catheter with the localization system.

Fig. 3 is a side elevation view of a reference catheter for use with the localization system.

Fig. 4 is a side elevation view of a first alternative embodiment of a reference catheter for use with the localization system, in which ultrasound transducers are included on a catheter of a type conventionally used in the RV apex.

Fig. 5 is a side elevation view of a second alternative embodiment of a reference catheter for use with the localization system, in which ultrasound transducers are included on a catheter of a type conventionally used in the coronary sinus.

Fig. 6 is a perspective view of a piezoelectric cylinder of a type which may be used on catheters used in the localization system, including those catheters shown in Figs. 3 - 5.

Fig. 7 is a side elevation view of the piezoelectric cylinder of Fig. 6 mounted on a catheter and modified to include a divergent lens.

Fig. 8 is a perspective view of a mandrel having a polymer piezoelectric wrapped around it for use with a reference catheter in combination with the localization system.

Fig. 9 is a side elevation view of a catheter for use with the localization system, which is provided with marking and ablation capabilities.

Fig. 10 is a perspective view of a first alternative embodiment of a catheter with marking and ablation capabilities for use with the localization system.

Figs. 11 and 12 are side section views of second and third alternative embodiments of catheters having marking and ablation capabilities for use with the localization system.

Fig. 13 is a side elevation view of a mapping catheter for use with the localization system. As with all of the catheters shown herein, the sizes of the electrodes and transducers are exaggerated for purposes of illustration.

Fig. 14A is a front elevation view of the mapping catheter of Fig. 13, showing the spacing of the basket arms.

Fig. 14B is a view similar to the view of Fig. 14A showing alternate basket arm spacing.

Fig. 15 is a cross-section view of the mapping catheter taken along the plane designated 15-15 in Fig. 13.

Fig. 16 is a plan view of an arm of the mapping catheter of Fig. 13.

Fig. 17 is a cross-section view of the arm of Fig. 16, taken along the plane designated 17-17.

Fig. 18 is a side elevation view of a linear lesion catheter for use in the localization system.

Fig. 19 is a side section view of the linear lesion catheter of Fig. 18.

5 Fig. 20 is a cross-section view taken along the plane designated 20-20 in Fig. 19.

Fig. 21 is a cross-section view taken along the plane designated 21-21 in Fig. 19.

10 Fig. 22 is a cross-section view taken along the plane designated 22-22 in Fig. 19.

Fig. 23 is a side section view, similar to the view of Fig. 19, of an alternative embodiment of a linear lesion catheter for use with the localization system.

15 Fig. 24 is a cross-section view taken along the plane designated 24-24 in Fig. 23.

Fig. 25 is a side section view, similar to the view of Fig. 19, of an alternative embodiment of a linear lesion catheter for use with the localization system.

20 Fig. 26 is a cross-section view taken along the plane designated 26-26 in Fig. 25.

Fig. 27A is a schematic drawing showing ultrasound ranging hardware and its interaction with the ultrasound hardware control and timing systems.

25 Fig. 27B is a schematic diagram illustrating in greater detail ultrasound ranging hardware and ultrasound hardware control and timing systems of the type shown in Fig. 27A.

Fig. 28A is a plot of the voltage over time on an ultrasound transmit line following initiation of a transmit pulse, and illustrates

the ringing which occurs on the transmit line following the transmit pulse.

Fig. 28B is a plot of the voltage over time on an ultrasound receive line which is located near the transmit line at the time the transmit pulse of Fig. 28A is initiated. The figure shows the ringing which results from the ringing on the transmit line, and also shows a receive pulse following the ringing.

Fig. 28C is a plot of the voltage over time on an ultrasound receive line which is located very close to a transmit wire at the time the transmit pulse of Fig. 28A is instituted, and it illustrates that the receive pulse may be lost in the ringing.

Fig. 28D is a plot of the voltage over time on an ultrasound transmit line which is short circuited immediately following the initiation of a transmit pulse.

Fig. 28E is a plot of the voltage over time on an ultrasound receive line which is adjacent to the transmit line represented in Fig. 28D. The figure shows that ringing is eliminated on the receive line when the transmit line is short circuited just after the transmit pulse is sent.

Fig. 29 is a schematic diagram illustrating a pulse generator circuit which includes a switch for short circuiting the transmit line just after the transmit pulse is sent.

Fig. 30A is a schematic illustration of the sample and hold system used for gating position information to the cardiac cycle.

Fig. 30B shows an EKG plot together with a plot of transducer coordinates and illustrates a sample and hold sequence which takes transducer coordinates at the end of diastole.

Figs. 31 and 32 illustrate the graphical user interface of the localization system. Fig. 31 illustrates display of anatomical

features, reference catheters, a linear lesion catheter, and burns formed in the heart using the linear lesion catheter. Fig. 32 illustrates display of the reference catheters, anatomical features, burns formed in the heart, and a basket catheter together with its mapping electrode positions.

Fig. 33 is a flow diagram illustrating use of the catheters of Figs. 3, 9 and 13 to treat ventricular tachycardia.

Figs. 34A-34C are a series of views of a heart illustrating certain of the steps of Fig. 33: Fig. 34A is an anterior section view of the heart showing placement of a reference catheter in the right ventricle and a marking catheter in the left ventricle. Fig. 34B is a lateral view of the heart showing a reference catheter in the coronary sinus. Fig. 34C is an anterior section view of the heart showing a reference catheter in the right ventricle and a mapping catheter in the left ventricle. Fig. 34D is a view similar to the view of Fig. 34C showing introduction of an ablation catheter into the mapping catheter.

Fig. 35 is a flow diagram illustrating use of the localization system together with the catheters of Figs. 3, 9, 13 and 18 to treat atrial fibrillation.

Figs. 36A -36C are a series of views of a heart illustrating certain of the steps of Fig. 35: Fig. 36A is an anterior section view of the heart showing placement of a reference catheter in the RV apex and a marking catheter in left atria; Fig. 36B is an anterior section view of the heart showing a linear lesion ablation catheter in the left atria; Fig. 36C is an anterior section view of the heart showing a mapping catheter in the left atria.

Figs. 37 through 42 illustrate a preferred embodiment of the model transformation system and method according to the present invention, in which:

Fig. 37 is a simplified block diagram illustrating the basic components of the model transformation system according to the preferred embodiment.

Fig. 38 is a simplified flow diagram illustrating basic operation of the model transformation system according to the preferred embodiment.

Fig. 39A is an example of a graphical display according to the preferred embodiment showing a three-dimensional model of a human heart prior to transformation of the model, superimposed with a representation of a reference catheter positioned within the heart.

Fig. 39B is an example of a graphical display similar to Fig. 39A, showing a model of a human heart superimposed with a representation of a reference catheter positioned within the heart. The drawing shows the model after it has been transformed to reflect information obtained using the reference catheter.

Fig. 40A is an example of a graphical display according to the preferred embodiment showing a three-dimensional model of a human heart prior to transformation of the model, superimposed with a representation of a probe positioned within the left ventricle of the heart.

Fig. 40B is an example of a graphical display similar to Fig. 40A, showing the model of a human heart superimposed with the representation of the probe positioned within the left ventricle. The drawing shows the model after it has been transformed to reflect information obtained using the probe.

Fig. 40C is a schematic drawing illustrating transformation of the model in response to input received by the system concerning the location of the probe. The drawing shows an anterior section view of a model of a human heart superimposed with a representation of a probe positioned within the left ventricle of the heart. Dashed lines and arrows illustrate the transformation that the model will undergo as a result of information obtained by the probe concerning the physical characteristics of the patient's heart.

Fig. 41A is an example of a graphical display according to a preferred embodiment, showing a three-dimensional model of a human heart superimposed with a representation of a probe positioned within the left ventricle of the heart.

Fig. 41B is an example of a graphical display similar to Fig. 41A, showing the model of a human heart superimposed with the representation of the probe positioned within the left ventricle. The drawing shows the model after it has been transformed to reflect information obtained using the probe.

Fig. 41C is a schematic drawing illustrating transformation of the model in response to input received by the system concerning the location of the probe. The drawing shows an anterior section view of a model of a human heart superimposed with a representation of a probe positioned within the left ventricle of the heart. Dashed lines and arrows illustrate the transformation that the model will undergo as a result of information obtained by the probe concerning the physical characteristics of the patient's heart.

Fig. 42 is a flow diagram illustrating a mode of operation for the system of the preferred embodiment.

Detailed Description

The model transformation system and method is designed for use in combination with a localization system that permits determination of the 3-D position of a medical device within a body. From the determined 3-D position, the 3-D locations of anatomical features in a region of interest may be derived and used to deform a 3-D graphical model of the region of interest so as to dynamically increase the conformity of the model with the actual region of interest.

Various types of prior art localization systems may be used in combination with the deformable model according to the present invention. Once such localization system is described U.S. Patent Nos. 5,391,199, 5,443,489, 5,480,422, 5,546,951, 5,568,809, 5,694,945 and 5,713,946 (each to Ben-Haim) which are incorporated herein by reference. That system utilizes antennas placed outside the body and on catheters placed within the heart. Electromagnetic fields are passed between the antennas and used to determine the locations of the distal tips of the catheters.

Other localization systems that are useful for obtaining the three-dimensional locations of catheters positioned within the body and that are thus suitable for use with the system of the present invention are described in U.S. Patent 5,697,377 entitled Catheter Mapping System and Method, Langbert et al, "The Echo-Transponder Electrode Catheter: A New Method for Mapping the Left Ventricle", Journal of the American College of Cardiology, Vol. 12, No. 1 (1988), and R.R. Fenici and G. Melillo, "Biomagnetically localizable multipurpose catheter and method for MCG guided intracardiac electrophysiology, biopsy, and ablation of cardiac

PATENT APPLICATION

Express Mailing Label: EM503277091US

arrhythmias", International Journal of Cardiac Imaging, 1991, Vol. 7, pp. 207-215, each of which is incorporated herein by reference.

Another localization system useful in connection with the present invention is an ultrasound localization system described in U.S. Application No. 08/905,090, filed August 1, 1997, entitled SYSTEM FOR ELECTRODE LOCALIZATION USING ULTRASOUND. A preferred embodiment of the present invention will be described with reference to this ultrasound localization system. It is important to note, however, that the scope of the invention is not limited to systems in which ultrasound localization is used.

For the purposes of this description, the term "physical characteristics" will be used in a broad sense to describe not only specific anatomical features within the body such as valves, organ walls, and other structures, but also to describe spaces within the body. The importance of such information will become clear as the system is described in detail.

For purposes of clarity, the localization system will first be described in connection with Figs. 1 through 36C. Afterwards, a preferred model transformation system and method according to the present invention will be described in connection with Figs. 37 through 42.

Localization System Overview

A localization system and procedure useful in combination with the deformable model will first be described in general terms. Specific examples of procedures which may be carried out using the system will be described in the Operation section of this description. The system is described primarily with respect to catheters in the heart, but it should be understood that the system is intended for

use with other medical devices and in other regions of the body as well.

Referring to Fig. 1, the localization system 100 uses one or more ultrasound reference catheters 10 to establish a three-dimensional coordinate system within a patient's heart. The system allows the positions of one or more additional catheters 12, 14, 16, to be represented graphically on a graphical user interface 124 relative to a coordinate system. This aids the clinician in guiding the additional catheter(s) 12, 14, 16 through the heart to locations at which they are needed to perform clinical procedures.

In one embodiment of such a localization system, the additional catheters include mapping catheters 14 for measuring electrical activity within the heart and ablation catheters 12, 16 for ablating selected regions of cardiac tissue. These catheters 12-16 may also be described as "electrophysiology catheters" or "EP catheters."

Each of the reference catheters 10 carries a plurality of ultrasound transducers, with there being a total of at least four such transducers employed during use of the system. The reference catheter transducers can function as ultrasound receivers by converting acoustic pressure to voltage, and as ultrasound transmitters by converting voltage to acoustic pressure. Each of the additional catheters 12, 14, 16 carries at least one ultrasound transducer which preferably functions as an ultrasound receiver but which may also function as a transmitter or a transmitter/receiver.

Using known techniques, the distance between each transducer and other ones of the transducers may be computed by measuring the respective time for an ultrasound pulse to travel from a transmitting transducer to each receiving transducer. These

PATENT APPLICATION

Express Mailing Label: EM503277091US

distance measurements are preferably carried out in parallel. In other words, when an ultrasound pulse is emitted by a reference catheter transducer, the system simultaneously measures the respective times it takes for the pulse to reach each of the other transducers being used in the system.

The velocity of an acoustic signal in the heart is approximately 1570 - 1580 mm/msec, with very small variations caused by blood and tissue. The time for an acoustic pulse to travel from one transducer to another may therefore be converted to the distance between the transducers by multiplying the time of flight by the velocity of an acoustic pulse in the heart (i.e. by 1570-1580 mm/msec). As detailed below, the localization system 100 uses this "time of flight" principal in combination with the geometric principal of triangulation to establish a three-dimensional coordinate system using the reference transducers on the reference catheter 10, and to then use the additional catheter transducers to track the location of an additional catheter 12, 14, 16, relative to the coordinate system.

During use of the localization system 100, one or more of the reference catheters 10 is introduced into the heart or the surrounding vasculature (or even into other areas such as the esophagus) and is left in place for the duration of the procedure. Once reference catheter(s) 10 are positioned within or near a patient's heart, the system first measures the distances between each of the reference catheter transducers using the "time of flight" principal. It then uses these distances to establish the relative positions of the reference transducers and therefore to establish a three-dimensional coordinate system.

Referring to Fig. 2, establishing the coordinate system requires placement of the reference catheter(s) 10 such that at least four

reference transducers, designated T_{REF1} through T_{REF4} in Fig. 2, are available to define a 3-dimensional coordinate system as follows: T_{REF1} through T_{REF3} , define the plane P at $z=0$; one reference transducer T_{REF1} defines the origin of the coordinate system; a line between T_{REF1} and T_{REF2} defines the x-axis of the system; and T_{REF3} lies in the plane $z=0$. The fourth reference transducer, T_{REF4} , lies on one side of the plane P, at $z>0$. Given these constraints, the coordinates of the reference transducers can be computed using the law of cosines. See, for example, Advanced Mathematics, A preparation for calculus, 2nd Ed., Cxford, A.F., Payne J.N., Harcourt Brace Jovanovich, New York, 1978, p. 160.

Each of the reference transducers T_{REF1} through T_{REF4} must be capable of both receiving and transmitting ultrasound pulses. As discussed, each reference transducer is separately made to emit acoustic pulses that are received by each of the other reference transducers so that the distances $d1$ through $d6$ shown in Fig. 2 are calculated using the respective times it takes for an acoustic pulse to travel between each pair of the reference transducers. These distances are triangulated to establish the positions of the reference transducers relative to each other, and therefore to establish a three-dimensional coordinate system.

Once a 3-dimensional coordinate system is established in the manner described, the three-dimensional location of an additional catheter transducer placed near or within the heart (such as a transducer on a mapping or ablation catheter 12, 14, or 16) can be calculated as follows. First, using the "time of flight" method, the distances between each of the reference transducers T_{REF1} through T_{REF4} and the additional catheter transducer (designated T_{CATH} in Fig. 2) are established, in parallel. In practice, these distances are

preferably also performed in parallel with the distance measurements that are made to establish the coordinate system. Next, using basic algebra and the law of cosines (see, e.g., the Advanced Mathematics text cited above), the coordinates of T_{CATH} relative to the reference transducers are calculated using the measured distances from T_{REF1} through T_{REF4} to T_{CATH} . This process is referred to as triangulation.

The locations of all or portions of the reference catheters may be displayed as well. The system is preferably programmed to extrapolate catheter position from the coordinates of the transducer locations based on models of the various catheters pre-programmed into the system, and to display each catheter's position and orientation on a graphical user display (see display 124 in Fig. 1). The locations of all or portions of the additional catheters (such as, for example, their distal tips, their electrodes or ablation sections, if any, or other sections which may be of interest) are displayed.

The reference catheter(s) 10 thereby establish an internal coordinate system by which the relative positions of EP catheter transducers in the heart may be calculated using triangulation and shown in real-time on a three dimensional display.

Ultrasound Catheters

Catheters of the type which may be used with the localization system 100 are shown in Figs. 3, 9, 13 and 18. These include a reference catheter 10 (Fig. 2), a marking and ablation catheter 12 (Fig. 9), a basket-type mapping catheter 14 (Fig. 13), and a linear lesion ablation catheter 16 (Fig. 18).

Reference Catheters

PATENT APPLICATION

Express Mailing Label: EM503277091US

Referring to Fig. 3, a reference catheter 10 which may be used with the localization system 100 is an elongate catheter having a plurality of ultrasound transducers 18 positioned at its distal end. The transducers 18 are piezoelectric transducers capable of transmitting and receiving ultrasound signals.

The reference catheters can be integrated with typical EP catheters by providing the ultrasound transducers described above. This allows the system to utilize the localization function using catheters which are already needed for the EP procedure. Thus, use of the system does not require the physician to use more catheters than would be used had the EP procedure been carried out without the localization function.

For example, referring to Fig. 4, the reference catheter 10a may be an RV apex catheter having a distal pair of EP electrodes 30, an ultrasound transducer 18a at the distal tip, and additional ultrasound transducers 18 proximally of the distal tip. It may also be a coronary sinus reference catheter 10b (Fig. 5) having at least three bipole pairs of EP electrodes 30 distributed over the section of the catheter that is positioned in the coronary sinus, and having at least three ultrasound transducers also distributed over the section of the catheter that is in the coronary sinus.

Referring to Fig. 6, a preferred transducer 18 is a piezoelectric cylindrical tube having inner and outer surfaces. The cylindrical transducer may be made of PZT-5H, PZT-5A, PMN (lead metaniobate or lead magnesium niobate) or other piezoelectric ceramic materials.

Electrodes 20 are positioned on the inner and outer surfaces of the transducer. The electrodes are metal surfaces not limited to materials such as sputtered chrome and gold, electroless nickel, or

fired silver. The piezoelectric ceramic is polarized in the thickness mode, i.e., between the two electrodes 20.

The cylinder includes an outside diameter (designated "OD" in Fig. 6) of approximately 0.040 to 0.250 inches, and preferably approximately 0.060 to 0.090 inches. The cylinder has a length L of approximately 0.020 to 0.125 inches and preferably approximately 0.030 to 0.060 inches. Wall thickness W is approximately 0.004 to 0.030 inches and preferably approximately 0.006 inches to 0.015 inches. The transducers 18 are spaced from one another along the catheter 20 (Fig. 3) by a distance of approximately 0.5 - 10 cm, and most preferably 1 - 3 cm.

Preferably, the localization system is operated using the same operating frequencies for all transducers. The optimal operating frequency for the system is determined by considering the resonant frequencies of the ultrasound transducers used for the catheters in the system. It has been found that, given the dimensions and thus the resonances of the preferred transducers being used in the system, the transducers are most preferably operated at a frequency of approximately 1.0 - 3.0 MHz, which in the case of the transducer 18 is the transducer resonance in the length mode. Transducer 18 further has a beam width of approximately 114° , where the beam width is defined as the angle over which the signal amplitude does not drop below 6 dB from the peak amplitude. If desired, a diverging lens 22 (Fig. 7), in the form of a spherical bead of epoxy or other material may be formed over the ceramic cylinder to make the signal strength more uniform over the beam width.

Referring to Fig. 8, the reference catheter transducers 18b may alternatively be formed of piezoelectric polymer films of copolymers such as PVDF. Such films would have thicknesses of

approximately 0.005 - 1.0 mm, and preferably approximately 0.007 - 0.100 mm, and would preferably include gold film electrodes on the inner and outer surfaces. As shown in Fig. 8, the polymer film would be wrapped around a mandrel 24 (which may be part of the catheter shaft 10c itself or a separate polymer plug inside the catheter 10). A transducer configuration of this type operates with a very large band width and does not have a specific resonance due to the polymer piezoelectric.

Electrode leads (not shown) are attached to the inner and outer transducer electrodes (such as electrodes 20 of Fig. 6). If piezoelectric ceramics are used as in Figs. 6 and 7, leads may be attached using low temperature solders which typically contain large proportions of indium metal. Leads may alternatively be attached with silver epoxy. It is important that the leads be attached using a minimum amount of material to minimize distortion of the acoustic field. In the case of the polymer transducers of Fig. 8, photolithographic techniques are typically used to create electrodes and their associated lead tabs. In this manner, the one side electroded polymer at the tab site does not contribute to the acoustic field. Leads are typically attached to these tabs with either low temperature indium based solders or with silver epoxy. Therefore, for these polymer transducers, the amount of material on the connection tab does not affect the acoustic field.

The reference catheter preferably includes at least four such transducers so that a three-dimensional coordinate system can be established using a single catheter. If desired, the reference catheter may have more transducers or it may have fewer transducers if more than one reference catheter is to be used to establish the three-dimensional coordinate system. Using more than four reference

PATENT APPLICATION

Express Mailing Label: EM503277091US

transducers is advantageous in that it adds redundancy to the system and thus enhances the accuracy of the system. When more than four reference transducers are used, the problem of determining the location of catheter transducers is over determined. The additional redundancy may provide greater accuracy if the measured distances between the reference transducers and catheter transducers are noisy. The overdetermined problem can be solved using multi-dimensional scaling as described in "Use of Sonomicrometry and Multidimensional Scaling to Determine 3D Coordinates of Multiple Cardiac Locations: feasibility and implementation", Ratcliffe et. al, IEEE Transactions Biomedical Engineering, Vol. 42, no. 6, June 1995.

Referring again to Fig. 3, a connector 32 enables the catheter 10 to be electrically coupled to the ultrasound ranging hardware 116 (described below and shown in Fig. 1).

Four twisted pairs 26 of Teflon coated forty-two gauge copper wire (one pair can be seen in the cutout section shown in Fig. 3) extend from connector 32 through the catheter 10. Each twisted pair 26 is electrically coupled to a corresponding one of the ultrasound transducers 18, with one wire from each pair 26 coupled to one of the transducer electrodes 20 (Fig. 6). When a transducer is to act as an ultrasound transmitter, a high voltage pulse (i.e, approximately 10 - 200V) is applied across the corresponding twisted pair 21 and causes the transducer 18 to generate an ultrasound pulse. When a transducer is to act as an ultrasound receiver, the ultrasound ranging hardware 116 (Figs. 27A - 27B, described below) awaits receive pulses of approximately 0.01 - 100 mV across the twisted pairs corresponding to receiving transducers.

Additional leads (not shown) couple the EP electrodes 30 to the EP hardware 114 (Fig. 1).

To facilitate manipulation of the reference catheter through a patient's vessels and into the heart, the reference catheter 10 may have a pre-shaped (e.g. curved) distal end.

Marking/Ablation Catheter

Referring to Fig. 9, the localization system 100 preferably utilizes a catheter 12 to identify the locations of anatomical landmarks (such as the septal wall) relative to the coordinate system so that the landmarks may be included on the three-dimensional display. Showing anatomical landmarks on the display correlates the three-dimensional coordinate system to discrete anatomical locations and thereby assists the physician in navigating EP catheters to the desired locations within the heart.

The marking catheter 12 is preferably a 7 French steerable catheter having one or more ultrasound transducer(s) 34 mounted at or near its distal tip. Preferably, the catheter 12 includes one transducer at or near its distal tip and a second transducer spaced from the distal tip by approximately 0.5 - 4.0 cm. The marking catheter 12 need not be one which is limited to use in marking anatomical sites. It can be a catheter useful for other purposes as well; the term "marking catheter" is being used in this description as a matter of convenience. Catheter 12 may also include an ablation electrode 36 at its distal tip, so that it may also be used to ablate tissue while the position of the ablation electrode 36 is tracked using the localization system 100. It may also include other electrophysiology electrodes 38 which may be used for pacing and/or mapping as desired by the user.

PATENT APPLICATION

Express Mailing Label: EM503277091US

The transducers 34 may be similar to the reference catheter transducers 18. While the outer diameter and wall thickness of the transducers 34 may differ from that of transducer 18 to accommodate mounting requirements, the length of the transducers 34 is preferably the same as that of the transducers 18 to assure a common operating frequency of approximately 1.0 - 3.0 MHZ.

Alternatively, the more distal transducer might be packaged differently than the reference catheter transducers. For example, referring to Fig. 10, the transducer 34 may be mounted just proximal of the distal ablation tip 36. Alternatively, a cylindrical transducer 34a or a plate transducer 34b may be positioned inside the distal ablation tip, in Figs. 11 and 12, respectively. An internal piezoelectric transducer would be embedded in a bead of epoxy 40 positioned in the catheter tip. This bead would preferably have a spherical contour across the distal end so that it would act as a divergent lens for the ultrasound energy. The metal forming the ablation tip 36 must be very thin (i.e., less than a small fraction of a wavelength) to facilitate the transmission of acoustic energy to and from an internal transducer.

The marking catheter 12 may additionally be provided with EP electrodes 38. As shown in Fig. 9, a handle 42 and a knob 44 for actuating a pull wire (not shown) allow the marking catheter 12 to be maneuvered through a patient's vessels and heart using conventional steering mechanisms. A connector 46 enables the catheter 12 to be electrically coupled to the EP hardware 114 and the ultrasound ranging hardware 116 (described below, see Fig. 1).

Mapping Catheter

Fig. 13 shows a first embodiment of a mapping catheter 14 for use with the localization system 100. The catheter 14 is of the type known in the art as a "basket" catheter. It includes an
5 elongate shaft 48 carrying a mapping basket 50 at its distal end. The basket 50 is formed of preferably eight arms 52. Arms 52 are constructed of ribbons of a shape memory material such as Nitinol. The shape memory material is treated such that the ribbons assume the basket structure shown in Fig. 13 when in an unstressed
10 condition.

The arms 52 may be concentrated at one section of the basket (Fig. 14A) so that during use mapping may be concentrated in one area of a cardiac chamber. The arms may alternatively be uniformly spaced as shown in Fig. 14B. Basket catheters of these
15 types are shown and described in U.S. Patent No. 5,156,151, the disclosure of which is incorporated herein by reference.

A sheath 54 is disposed around shaft 48. Sheath 54 is longitudinally slidable between the proximal position in Fig. 13 and a distal position in which the basket 50 is compressed within it.
20 During use the sheath 54 is moved to the distal position to compress the basket before the catheter 14 is inserted into the patient, so that the basket can be easily moved through the patient's vessels and into the patient's heart. Once the basket is within the desired chamber of the patient's heart, the sheath is withdrawn, the basket
25 is opened into its expanded condition, (either by spring action of the arms 52 or by a separate actuator) and the arms to map electrical activity of the chamber wall.

Each arm 52 of the basket catheter 14 carries a plurality of EP mapping electrodes 56 designed to detect the electrical activity of

PATENT APPLICATION

Express Mailing Label: EM503277091US

underlying cardiac tissue. A plurality of ultrasound receiving transducers 58 are also mounted to each arm 52. Preferably, the mapping electrodes 56 and the ultrasound transducers 58 alternate with each other along the length of each arm 52, although there need not be one-to-one correspondence between the transducers and electrodes.

Fig. 16 is a plan view of one arm 52 of basket catheter 14, and Fig. 17 is a side section view of the arm of Fig. 16. As shown, the mapping electrodes 56 and ultrasound transducers 58 are preferably formed on a flex circuit 60 which is attached to the arm 52. Copper leads 62 are formed on the flex circuit and each lead is electrically connected to one of the EP electrodes 56 and one of the ultrasound transducers 58, and to the EP and localization hardware 110 (Fig. 1). Each arm 52, including its associated flex circuit 60, is covered in polyethylene shrink tubing 64, with only the electrodes 56 being exposed through the shrink tubing 64.

Referring to Fig. 16, a preferred piezoelectric transducer for the mapping catheter comprises a flat piezoelectric ceramic plate 66. The plate 66 may be made of PZT-5H, PZT-5A, PMN (lead metaniobate or lead magnesium niobate) or other piezoelectric materials.

The transducer includes a depth D and length L, each of approximately 0.010 to 0.060 inches, and preferably approximately 0.025 to 0.040 inches. The transducer has a wall thickness W of approximately 0.004 to 0.030 inches and preferably approximately 0.006 to 0.015 inches. The length and depth resonances of the transducer fall in the range from 1.0 MHz to 3 MHz and thus contribute to the overall performance of the system. The beam

PATENT APPLICATION

Express Mailing Label: EM503277091US

width considerations are the same as those described above for the reference catheter transducers 18 (Fig. 6).

5 Electrodes 68a, 68b are positioned on the upper and lower flat surfaces of the plate. The electrodes are metal surfaces not limited to materials such as sputtered chrome and gold, electroless nickel, or fired silver. The piezoelectric ceramic is polarized in the thickness mode, i.e., between the two electrodes.

10 The mapping catheter transducers 58 may alternatively be formed of piezoelectric polymer films of copolymers such as PVDF. Such films would have thicknesses of approximately 0.005 - 1.0 mm, and preferably approximately 0.007 - 0.100 mm, and would preferably include gold film electrodes on the inner and outer surfaces. The polymer film would preferably be taped to the printed wiring board of the basket arm, and leads attached to the top
15 electrodes in a manner similar to that mentioned above for the reference catheter transducers. Alternatively, the polymer film could be used to form the entire flex circuit.

20 Lead wires 70a, 70b extend between the copper leads 62 and the electrodes 68a, 68b. It is important to note that each of the leads 62 electrically connects both an ultrasound transducer 58 and an EP electrode 56 to the EP and localization hardware 110. Each lead 62 therefore carries electrical activity measured by EP electrodes 56 as well as receive signals from the ultrasound transducers 58 to the hardware 110. It is possible to do this
25 because EP signals have a lower frequency (i.e., on the order of 1 Hz - 3 kHz) than the ultrasonic signals, which have frequencies of approximately 500 kHz - 30 MHz. Thus, the EP signals can be removed from the recorded signal using low-pass filtering while the ultrasound signal can be removed using high pass filtering.

PATENT APPLICATION

Express Mailing Label: EM503277091US

Combining EP and ultrasound signals on the same lead 62 has the advantage of reducing the total number of conductors in the catheter 14. While this is advantageous, it is not a requirement for functionality of the system. Naturally, the system may also be provided using separate leads for the EP and ultrasound signals.

For both piezoelectric ceramic and polymer transducers, one lead 70b will most typically be attached by bonding the bottom electrode 68b of the piezoelectric (e.g., plate 66) with silver epoxy to the printed circuit of the basket arm. Leads 70a may be attached to the top electrodes 68a in a manner similar to that set forth with respect to the reference catheter transducers. For the piezoelectric ceramics 66, the top lead 70a may be attached with low temperature solders which typically contain large proportions of indium metal. It is important that the leads be attached using a minimum amount of material to minimize distortion of the acoustic field. Top leads 70a may also be attached with silver epoxy. In the case of the polymer piezoelectrics, metallization of the electrodes and leads is typically achieved using photo lithographic techniques. In this manner, the one side electroded polymer at the lead site does not contribute to the acoustic field as discussed previously for the polymer transducer of the reference catheter.

Acoustic wave propagation does not occur across a vacuum or air gap, consequently it is necessary to provide a rubber path or a path through an insulating polymer in order to fill air gaps around the transducers. For example, after the top lead 70a has been attached, the entire top surface and surrounding areas including the inner surface of the shrink tubing is coated with a rubber primer. Subsequently, the area between and around the top surface of the

piezoelectric and the shrink tubing is filled with a silicone rubber material.

Alternatively, the top surface of the piezoelectric and the electrical lead may be coated with an insulating polymer. After the heat shrink tubing is attached to the basket strut, a small area over and around the top electrode of the ceramic may be cut out of the shrink tubing to provide an unobstructed exposure of the transducer to the blood field.

The EP electrodes 56 are preferably platinum black electrodes having a size of approximately 0.009 x 0.030 inches. For these small electrodes, platinum black is used for low impedance, i.e., approximately less than 5.0 k Ohms over the frequency range (approximately 1 Hz - 3 kHz) of interest for EP signals. This is important in that it prevents the impedance of the ultrasound transducers from loading the output of the EP electrodes.

Fig. 15 is a cross-section view of the portion of the catheter 14 which is proximal of the basket 50. The catheter shaft 48 is formed of an inner shaft 72 and an outer, braided shaft 74 preferably made from stainless steel braid of a type conventionally known in the art. The inclusion of the braid improves the torque characteristics of the shaft 48 and thus makes the shaft 48 easier to maneuver through patient's vessels and heart.

Inner shaft 72 includes a center lumen 76 through which ribbon cables 78 extend. Leads (not shown) are formed on the ribbon cables 78 and function to carry signals corresponding to signals received by the ultrasound transducers 58 and by the electrophysiology electrodes 56 to the system hardware 110 (Fig. 1). An ablation catheter lumen 80 extends through the shaft 48 and allows an ablation catheter such as catheter 12 to be introduced

through the shaft 48 and into contact with tissue surrounding the basket 50.

Inner shaft 72 further includes a deflection lumen 82. A pull wire (not shown) extends through the deflection lumen 82 and facilitates steering of the basket using means that are conventional in the art.

Linear Lesion Ablation Catheter

Figs. 18 through 26 show a linear lesion ablation catheter 16 for use with the localization system 100. Catheter 16 is an elongate shaft preferably constructed of a thermoplastic polymer, polyamid ether, polyurethane or other material having similar properties. An ablation section 84, the section of the catheter 16 at which ablation is carried out, is located at the distal end of the shaft.

As shown in Fig. 18, an elongate window 86 is formed in the wall of the ablation section 84. The window 86 may be made from heat shrink polyethylene, silicone, or other polymeric material having a plurality of small holes or perforations formed in it. It may alternatively be formed of the same material as the remainder of the shaft and simply include a plurality of holes formed through it.

Referring to Fig. 19, a foam block 88 is disposed within the catheter, next to the window 86. The foam block 88 is formed of open cell polyurethane, cotton-like material, open-cell sponge, hydrogels, or other foam-like materials or materials that are permeable by conductive fluids. A plurality of RF ablation electrodes 90 line the edge of the foam block 88 such that the foam block lies between the electrodes 90 and the window 86.

5 Ultrasound transducers 92 are positioned at the distal and proximal ends of the foam block 88. The transducers 92 are preferably formed of piezoelectric ceramic rings having electrodes bonded to their inner and outer surfaces, although the transducers may also be formed in a variety of alternative shapes.

10 Referring to Figs. 20 - 22, several lumen extend through the catheter 16. The first is a fluid lumen 94 that extends the length of the catheter 16 and is fluidly coupled to a fluid port 96 (Fig. 18) at the proximal end of the catheter. It should be noted, with reference to Fig. 20, that the walls of the fluid lumen are cut away at the ablation section 84 to accommodate placement of the foam block 88 and the RF electrodes 90 within the catheter.

15 A pair of lead lumen 98 house lead wires 100 that carry RF energy to the electrodes 90 and lead wires 102 that carry voltage signals from the transducers 92. A fourth lumen 104 houses a Nitinol core wire 106 which provides rigidity to the catheter.

20 Because breaks in a linear lesion can reduce the success of an ablation procedure by leaving a path through which current may travel during atrial fibrillation episodes, the fluid lumen, foam, and window are provided to improve the coupling of the RF energy to the cardiac tissue to minimize the likelihood of breaks in the lesion.

25 Specifically, during use, the window 86 of ablation section 84 of the apparatus is positioned adjacent to the body tissue that is to be ablated. RF energy is delivered to the electrodes 90 while saline or other conductive fluid is simultaneously delivered through the fluid lumen 94. The conductive fluid passes out of the fluid lumen 94 and into the foam 88, and contacts the electrodes 90. The fluid also flows through the window 86 into contact with the body tissue, thereby improving the coupling of the RF energy from the electrodes

90 to the tissue and improving the efficiency of the ablation of the tissue.

Using a conductive liquid dispersed over the desired area as a mechanism for coupling RF energy to the tissue produces lesions having greater continuity (and thus fewer breaks through which current can pass during atrial fibrillation episodes) than lesions formed by apparatuses that rely solely on direct contact between the electrodes and the body tissues, decreasing the likelihood of thrombus formation on the electrodes and thus decreasing the chance of an embolism. The foam and the window improve ablation in that the conductive liquid is uniformly dispersed within the foam and then is focused onto the body tissue as it passes through the holes or pores in the window. This concept, and several alternate ways of configuring linear lesion catheters that may be adapted to include ultrasound transducers and used in the localization system 100, are described in published International Application PCT/US96/17536, the disclosure of which is incorporated herein by reference.

Figs. 23 and 24 show a first alternative embodiment of a linear lesion catheter for use with the localization system 100. The first alternative embodiment 16a differs from the embodiment of Fig. 19 primarily in the shape and placement of the transducers. Transducers 92a of the first alternative embodiment are piezoelectric chips embedded within the foam block 88. Each transducer 92a includes a pair of electrodes on its opposite faces and is encapsulated in an insulating cocoon 108 of epoxy, acrylic, or silicone rubber which prevents the fluid in the foam from creating a short circuit between the electrodes.

A second alternative embodiment of a linear lesion catheter is shown in Figs. 25 and 26. The second alternative embodiment also differs from the preferred embodiment only in the form and placement of the transducers. Each transducer 92b and its leads 102b is inside an epoxy capsule 109 embedded in the foam block 88. It should be noted, then, that only the RF electrode leads 100 extend through the lumen 98. The leads 102b of the second alternative embodiment extend through fluid lumen 94 as shown.

System Components

Referring to Fig. 1, the system 100 generally includes amplification and localization hardware 110, catheters 10, 12, 14 and 16, and a microprocessor workstation 112.

Hardware 110 includes conventional signal amplifiers 114 of the type used for electrophysiology procedures (for example, the Model 8100/8300 Arrhythmia Mapping System available from Cardiac Pathways Corporation, Sunnyvale, California). It also includes ultrasound ranging hardware 116 and an ultrasound hardware control and timing component 118 which together initiate, detect, and measure the time of flight of ultrasound pulses emitted and received from the ultrasound transducers on the reference and EP catheters 10-16.

Signal amplifiers 114 and the ranging hardware 116 and controller 118 are electronically coupled to a microprocessor workstation 112. The microprocessor work station 112 is designed to control the system hardware and the data processing for both the EP and ultrasound functions of the system, and to generate a visual display of EP and catheter position data for use by the clinician.

PATENT APPLICATION

Express Mailing Label: EM503277091US

For EP functions, the microprocessor 112 includes an amplifier controller 120 that delivers mapping, and/or pacing commands to the EP signal amplifiers 114. Signal processors 122 receive data corresponding to electrical activity measured by the mapping catheters 14, 16 and generate graphical representations of the measured data for display on graphical interface display 124. The mapping signals shown on the graphical display can represent any number of parameters or characteristics, such as measured signal values or impedance values, indicators of electrode contact, or indicators of the probability that there is an arrhythmogenic site in the area, etc.

Ultrasound hardware controller 118 and a triangulation processor 126 control the catheter localization functions and data processing. During use, controller 118 directs the ultrasound ranging hardware 116 to initiate an ultrasound pulse from a selected transmitting transducer. It further directs the hardware 116 to (1) detect, in parallel, voltages corresponding to reception of the ultrasound pulse by the receiving transducers, and (2) measure the elapsed time (time of flight) between transmission of the ultrasound pulse and its detection by the selected receiving transducers. Triangulation processor 126 receives data corresponding to these time of flight measurements from the ranging hardware 116 and uses it to calculate the locations of the EP catheter transducers relative to the reference transducers (see Localization System Overview). Data corresponding to catheter position, as calculated from transducer locations, and measured EP signals is shown in graphical form on graphical user interface display 124.

The ultrasound ranging hardware 116 may be configured to detect an acoustic pulse received by a receiving transducer in a

number of ways. For example, if the transmitting transducer is made to generate a short burst of high frequency ultrasound energy, the hardware 116 may be configured to detect the first signal excursion above or below a predetermined maximum and minimum voltage threshold, or the peak of a received signal. Alternatively, the transducer may be made to generate a continuous wave of low frequency ultrasound, in which case the hardware 116 would be configured to measure the difference in phase between the standing wave as generated by the transmitting transducer and as detected by the receiving transducer.

Referring to Fig. 27A, the ultrasound ranging hardware 116 includes a plurality of channels 128a, 128b, each of which is electronically coupled to one of the ultrasound transducers in the system. Depending on whether a transducer is intended to transmit and receive ultrasound signals (as in the case of a reference catheter transducer 18) or to receive ultrasound signals only (as in the case of an additional catheter transducer 34, 58 or 92), a transducer's corresponding channel circuitry may be configured to permit transmission and receipt of ultrasound signals by the transducer, or it may be configured only to allow receipt of signals by the transducer. Accordingly, transmit/receive channels 128a are each connected to a corresponding one of the reference catheter transducers 18 (Fig. 3), and receive channels 128b are each connected to a catheter transducer 34, 58, 92 (e.g., Figs. 9, 13 and 19).

Referring to Fig. 27B, the circuitry of each of the channels 128a, 128b generates digital data corresponding to the time of flight of an ultrasound transmit pulse from a transmitting transducer to the transducers corresponding to each of the channels 128a, 128b.

PATENT APPLICATION

Express Mailing Label: EM503277091US

Each channel 128a, 128b includes an amplifier 130 which amplifies voltage signals generated by the ultrasound transducers in response to receive pulses. The transmit/receive channels 128a additionally include transmitters 132 which, in response to signals from transmit and receive controller 142 (discussed below), apply voltages across the reference transducers 18 to trigger ultrasound pulses.

Each channel 128a, 128b further includes a threshold detector 134 which triggers a latch 136 once a received signal exceeds a threshold level. Latch 136 is coupled to distance register 138 which is in turn coupled to place distance output data onto data bus 140 upon activation of the latch 136.

Ultrasound hardware control and timing component 118 includes transmit and receive controller 142. Controller 142 is electronically coupled to a system clock 141 that drives a distance counter 144, and to a threshold amplitude generator 146 which provides the threshold reference input for threshold detectors 134.

As will be discussed in greater detail, count values from the distance counter 144 are used by the system 100 to calculate the distances between transmitting transducers and receiving transducers. Because system clock 141 drives the distance counter 144, it is the frequency of the system clock that determines the resolution of measured distances between transducers. The higher the frequency of the clock, the greater the resolution of the distance measured. Clock 141 is therefore a high frequency counter which preferably operates at least approximately 5 - 50 MHz, which is equivalent to a resolution of approximately 0.3 - 0.03 mm.

The threshold amplitude generator 146 produces time varying positive and negative thresholds that are used as inputs to the threshold detectors 134 of each channel 128a, 128b. Preferably,

PATENT APPLICATION

Express Mailing Label: EM503277091US

one threshold amplitude generator 146 is used for the entire system in order to minimize the amount of hardware in the system.

However, the system may alternatively use a separate threshold amplitude generator for each channel, or separate threshold amplitude generators for different groups of channels. For example, different threshold amplitude generators may be used for different types of receiving transducers, since some produce weaker signals and therefore require lower thresholds. As another alternative, a fixed threshold may be used together with a variable gain amplifier in place of amplifier 130.

The threshold amplitudes are preferably varied by the threshold amplitude generator 146 so that they are large at the time a transmit pulse is initiated and so that they decrease as time passes following transmission of a pulse. Using a variable threshold rather than a fixed one is beneficial because the dynamic range (i.e., the ratio of the largest signal to be detected to the smallest signal to be detected) is quite large, and may even be as high as 70 dB due to factors such as anisotropy of the transit and receive beam profiles, signal decay due to ultrasound wave propagation, and attenuation of the signal caused by blood and tissue. Because transducer receiving wires for a catheter based system must be closely spaced, a fixed dynamic range of this magnitude could lead to erroneous data, because cross-talk between the closely spaced receiving wires could be interpreted by the system to be actual receive signals.

It should be noted that both positive and negative thresholds are used so as to increase the accuracy of the detection time, since a negative oscillation of a transmit pulse may reach the detection threshold before a positive oscillation. Latch 136 will therefore be

triggered by whichever of the positive or negative thresholds is achieved first.

When a transmit pulse T (Fig. 28A) is being sent to a transducer, oscillation, or "ringing", designated " R_T ", can occur on the corresponding twisted pair 26 (Fig.3). The ringing in the transmit line is not problematic in and of itself. However, in catheters such as the reference catheter 10 which includes transducers which can both transmit and receive ultrasound signals, the close proximity of the transmitting and receiving lines can cause the ringing to cross over to the receiving line. This problem arises most frequently when the system is computing the relative orientations of the reference transducers 18 (Fig. 3) in order to establish the three-dimensional coordinate system, since that procedure requires measuring the time it takes for a pulse emitted by one of the reference transducers 18 to be received by the other reference transducers 18 on the same catheter. The ringing (which is designated " R_R " in Figs. 28B and 28C) can be of similar magnitude to a receive signal "S" and can therefore make it difficult to determine whether a receive signal has been detected.

If the transmitting and receiving transducers are far apart, a receive signal on a receiving line (such as twisted pair 26) will be measured by the ultrasound system circuitry despite the ringing, because transmission of the receive signal on the receiving line will happen only after the ringing has diminished. See Fig. 28B. However, if the transmitting and receiving transducers are close together (i.e., separated by less than approximately 2 cm), the receive pulse will be lost in the ringing on the receive line, because the receive pulse will reach the receiving line while the ringing is still occurring. See Fig. 28C.

It has been found that this problem may be avoided by including circuitry which will short the conductors of the transmit line immediately after the transmit pulse is sent. An example of such circuitry is shown in Fig. 29. The circuit includes the pulse generator 148 and center tapped transformer 150 which comprise basic pulse generating circuitry, plus a switch 152 which is closed immediately after a transmit pulse in order to short the ringing to ground. A small impedance 154 is placed in series with the switch in order to dampen the ringing through the short circuit. As illustrated in Figs. 28D and 28E, by eliminating the ringing from the transmitting line, the switch eliminates the ringing from the receiving line as well.

Referring again to Fig. 27B, during use of the system, each transmit/receive channel 128a is sequentially selected for transmission of a transmit pulse, and all channels 128a, 128b are simultaneously selected for parallel reception of distance data. Transmit and receive controller 142 selects which of the transmit/receive channel 128a will initiate an ultrasound pulse, and cycles through each transmit/receive channel, causing sequential transmission of pulses by the reference transducers 18 (Fig. 3). It uses the system clock 141 to generate a lower frequency transmit clock, which in turn controls how often ultrasound pulses are transmitted.

Each time a transmit pulse is to be initiated, the transmit and receive controller 142 performs the following sequence of steps. The distance counter 144 is first reset to zero, and the threshold amplitude generator 146 is reset. A detection hold off and reset signal is next sent by controller 142 to all channels 128a, 128b. This resets the latch 136 for each channel and prevents it from

PATENT APPLICATION

Express Mailing Label: EM503277091US

latching for a specified time period to prevent detection due to electromagnetic coupling of ringing after transmission of a transmit pulse. This "hold off" period is determined by the smallest distance within the patient that is to be measured, and is calculated according to the following equation:

hold off period = smallest distance * 1/(velocity of transmit signal).

Thus, if the smallest distance to be measured is 10mm, the "hold off period" is:

$$10mm * \frac{1}{1.5 \frac{mm}{\mu sec}} = 6.66 \mu sec$$

After the hold off and reset signals, a transmit control signal is sent to a selected one of the transmit/receive channels 128a, causing it to initiate a transmit pulse. Shortly afterwards, a signal is sent to the same transmitter to initiate damping in order to prevent/reduce ringing as described above.

When a transmit pulse is initiated, the distance counter 144 is simultaneously activated. After a transmit pulse is triggered, each channel 128a, 128b "listens for" a receive pulse. When the threshold detector 134 for a particular channel detects a receive pulse that exceeds the threshold set by the threshold amplitude generator 146, the latch 136 for that channel is activated. Once the latch 136 is activated, a load data command is sent to the associated distance register 138 and the current contents of the distance counter 144 are loaded into the distance register 138 for

that channel. This data is subsequently placed on the distance data bus 140 along with data indicating which channel transmitted the pulse. Thus, the data bus receives a number of distance values which correspond to the number of transmit/receive and receive only channels. These distance values are then used by the triangulation processor 126 (Fig. 1) to determine the relative positions of the ultrasound transducers, and the microprocessor 112 uses the position data to create a three-dimensional display of the catheters.

Graphical Display Features

As described, the three-dimensional positions of the integrated ultrasound transducers (such as those on catheters 10, 12, 14 and 16) may be continuously displayed in real-time on the graphical user interface display 124 (Fig. 1). The three-dimensional positions of the catheters (10, 12, 14 and 16), or portions thereof, may also or alternatively be continuously displayed based on the position of the transducers by extrapolating the catheter position using a known model of the catheter programmed into the system. The three-dimensional positions of the transducers and/or catheters may also be stored in the system's memory and selectively displayed on the graphical display user interface display 124 as required during a procedure.

For example, data corresponding to electrode locations on a mapping basket 14 may be saved in the system memory, together with data representing EP measurements taken by EP electrodes corresponding to the transducer locations. If, after the mapping basket 14 has been removed from the patient, the user wishes to guide an ablation catheter to a location corresponding to one of the basket electrodes, s/he may elect to display the saved location

PATENT APPLICATION

Express Mailing Label: EM503277091US

information for the basket simultaneously with the real time position of the ablation catheter.

The graphical user interface is further provided with several additional functions that improve the accuracy and usefulness of the system.

For example, the microprocessor 112 includes software which enhances the accuracy of the system by "gating out" the effects of cardiac motion on the position data calculated for the transducers and/or catheters. Because a beating heart contracts and expands with each beat, the catheter will move with the heart throughout the cardiac cycle even when a catheter is at a mechanically stable location within the heart. Thus, a real time display of the catheter (or transducer) position would show the catheter or transducer moving on the display because of the cardiac movement.

Such movement of the catheter/transducer on the display does not present problems in and of itself. However, if the user elects to save in the system memory the position of the catheter so that it may be used later during the procedure (such as to indicate anatomical landmarks, ablation locations, mapping locations, etc.), the effects of the movement on the saved locations can lead to inaccuracies if the user attempts to navigate a catheter (shown in real time on the display) with respect to the representation on the graphical display of the previous catheter position data.

To eliminate this problem, the patient's electrocardiogram (EKG) is monitored during use of the system, and the EKG is used to synchronize the acquisition of position data so that all position data is acquired at the same point in the cardiac cycle. Thus, for example, when EP signals are recorded from catheters having integrated localization transducers, the relative position/location

PATENT APPLICATION

Express Mailing Label: EM503277091US

information for the EP electrodes is accurate when displayed because all of the location information will have been collected during the same phase of the cardiac cycle. Gating is similarly carried out for the ablation and marking catheters, by collecting the appropriate position/location data for such catheters and the anatomical landmarks during the same phase of the cardiac cycle.

Fig. 30B shows an EKG signal along with corresponding electrode position data recorded over the cardiac cycle. It has been found that the end of diastole, at the Q-R wave of the EKG signal, is a convenient point for gating the position measurements. Fig. 30A schematically shows a gating system in which a patient's EKG signal is passed through an amplifier 302 and a detector 304 which initiates a sample and hold sequence 306 of position data when the initiation of a Q-R wave is detected.

The user preferably has the option of showing the gated position, or the actual (moving) position, or both on the real time display. The actual position of a catheter may be useful for assessing whether a catheter is in firm contact with the wall of the heart, because if the catheter is spaced away from the wall it will not move with the wall. A display of actual position may also be helpful during steering of a catheter because it provides more rapid feedback of a catheter's position and orientation.

It should be emphasized, however, that gated position information is essential during navigation of a catheter to a location which has been saved in the three-dimensional display, because unless the catheter position and the stored location are gated to the same point in the cardiac cycle, the user cannot be certain that the catheter has been navigated to the proper location.

Similarly, if EP signals are to be displayed in the form of an isochronal map on the three-dimensional display, the position used in the isochronal map to display an activation time for that location should be an EKG gated location.

5 Similar gating may also be provided to eliminate inaccuracies in location information due to the rising and falling of the chest during respiration. For respiratory gating, chest movement would be monitored using a bellows or other device and the sample and hold sequence would be triggered at a desired portion of the respiratory cycle.

10 Referring to Fig. 31, the gated positions of lesions and anatomical landmarks may be stored in the system software and added and deleted from the display as needed by the user by manipulating a cursor using a mouse or other user input device to the appropriate item in marker box 156.

15 The microprocessor 112 is preferably further provided with software which allows the physician to manipulate the display in many ways so that the maximum benefit may be obtained from the system. For example, referring again to Fig. 31, the user can rotate the display in three-dimensions by guiding the cursor to the appropriate icon in manipulation box 158. The user may likewise "zoom" towards or away from the image in the same manner. S/he may also elect which of the catheters 10, 10a, 12, 16 to display in real time using real time box 156.

20 The system further allows the user to select one of the standard orientations used in fluoroscopy such as anterior-posterior ("AP"), lateral, right anterior oblique ("RAO") or left anterior oblique ("LAO") by selecting the appropriate icon in orientation box 160. In the RAO view, the plane formed by the aortic-valve ring ("AV ring")

is approximately perpendicular to the plane of the display, with the end of the coronary sinus pointing to approximately the 2 - 3 o'clock position on the AV ring. In the LAO view, the apex of the heart is oriented such that it "points" towards a user viewing the display.

5 When the system 100 is used is a preferred mode, the transducers of a reference catheter positioned in the coronary sinus ("CS reference catheter") define the AV ring, and the distal tip of a second reference catheter is positioned in the RV apex ("RV apex catheter"). The system can orient the display to an RAO orientation
10 by deriving the location of the AV ring from the location of the transducers on the CS reference catheter, and re-orienting the display until the AV ring is perpendicular to the display and until the distal tip of the CS reference catheter points towards the 2 o'clock position.

15 With the AV ring perpendicular to the display, the system may also display straight anterior, posterior, left lateral, and right lateral views by orienting the CS catheter distal tip at the 12 o'clock, 6 o'clock, 3 o'clock, and 9 o'clock positions, respectively.

20 Similarly, the system can orient the display to an LAO orientation by deriving the location of the RV apex from the locations of the transducers on the RV apex catheter, and by orienting the display so that the RV apex points out of the display.

Operation

25 Two examples of procedures which may be carried out using the localization system 100 will next be described. It should be appreciated, however, that the system 100 may be utilized in any procedure in which three-dimensional navigation of devices relative to one another is required.

Fig. 33 is a flow diagram giving a sample methodology for using the localization system 100 for diagnosis and treatment of ventricular tachycardia. The steps shown in the flow diagram will be discussed with reference to the illustrations of the heart shown in Figs. 34A through 34D.

First, step 200, a reference catheter 10 is introduced into the inferior vena cava and is passed under fluoroscopy into the right ventricle (designated RV). The catheter is positioned with its distal tip at the apex (A). A second reference catheter 10a is introduced via the superior vena cava into the coronary sinus (a vein, shown and designated CS in Fig. 34B, that extends around the edge of the AV ring separating the left atrium and the left ventricle). The reference catheters may be positioned elsewhere without departing from the scope of the invention. However, the RV and CS are suitable locations because they allow the catheters to remain mechanically stable within the heart. Moreover, these reference catheters will include the EP electrodes equivalent to those already used on CS and RV apex catheters, i.e. they will replace conventional CS and RV apex catheters. Placement of the reference catheters using these approaches therefore does not require introduction of additional introducer sheaths or catheters into the patient.

Throughout the procedure, the system calculates the relative positions of the ultrasound reference transducers 18 (Fig. 3) using time-of-flight measurements and triangulation, establishes the three-dimensional coordinate system, and displays at least a portion of the reference catheter on the graphical interface 124.

Next, referring again to Fig. 34A, marking catheter 12 is preferably (but optionally) introduced into the left ventricle. Catheter

12 is guided under fluoroscopy to sequentially position its distal tip against various anatomical landmarks, such as the apex, septal wall, lateral wall, etc. The location of each transducer 34 (Fig. 9) relative to the reference catheters is calculated again using time-of-flight measurements and triangulation. The location of the catheter distal tip and thus the location of the anatomical site is extrapolated from the transducer location using a model of the catheter 12 pre-programmed into the system, and it may be subsequently displayed on the graphical display. Once the desired landmarks are identified and displayed, the marking catheter 12 is removed from the heart. Steps 202 - 208.

Referring to Fig. 34C, basket catheter 14 (Fig. 13) is next introduced under fluoroscopy into the left ventricle (LV), at a location at which the clinician suspects there may be arrhythmogenic tissue. Step 210. Because the basket arms 52 include ultrasound transducers 58 as well as mapping electrodes 56, the locations of the mapping electrodes can be determined relative to the reference catheters and displayed on the graphical display based on a model of the basket 50 programmed into the system. Step 212.

Electrical activity within the heart is recorded from the mapping electrodes 56 and mapping data derived from the recorded activity is displayed on the graphical display. The EP signal display may be displayed separately from the three-dimensional display, such as in the signal display window 162 shown in Fig. 32. Each graph in the signal display window 162 represents the voltage data over time, as measured by one of the EP electrodes 56 on the basket catheter 14.

The EP signals may alternatively be displayed in the form of an isochronal map on the three-dimensional display. A display of

100400304.000398
this type would be generated by first placing an activation time on each signal, where an activation time is the time at which the tissue under a mapping electrode 56 activates. The activation times can be either placed automatically using an algorithm or manually by the user. The map is generated by showing a color on the three-dimensional display that represents an activation time at a location corresponding to the location of the electrodes that measured the signal. It may be in the form of discrete color dots or an interpolated color surface or sheet which passes through the locations of the EP electrodes.

The EP display may alternatively take the form of an isopotential display on the three-dimensional display. An isopotential map is similar to an isochronal map except that it is a time varying color display that is proportional to signal amplitude rather than a static display of activation time.

Other mapping data derived from the EP signals may also be shown on the display. For example, data indicating the adequacy of contact between the electrodes and the tissue, or indicating the probability that there is an arrhythmogenic site at the mapped location may be represented on the display. The physician may induce electrical activity for subsequent measurement by pacing the heart from the basket electrodes 56. Step 214.

If an arrhythmogenic region is identified by the clinician on the visual display, a marking and ablation catheter 12 (Fig. 9) is inserted into the center lumen 80 of mapping catheter 14 (Fig. 15) and is guided into the left ventricle. The three-dimensional position of the ablation electrode 36 is displayed (using ultrasound receiving transducer 18 to track its position) in real time to aid the physician in guiding the electrode 36 to the arrhythmogenic region of the

endocardium. Fig. 34D and step 216. Once the ablation electrode is positioned at the arrhythmogenic region, ablation is carried out by supplying RF energy to the electrode 36.

5 The clinician next attempts to induce ventricular tachycardia by pacing the site from the basket catheter electrodes 56 or from electrodes on another catheter. Step 220. If VT cannot be induced, the procedure is considered successful and the catheters 10, 14 are removed. Step 222. If VT is induced, additional mapping and ablation steps are formed until the VT appears to be eradicated.

10 It should be noted that if mapping is carried out using a basket catheter that is not provided with a center lumen 39, the basket catheter may be removed after its electrode positions and corresponding mapping signals (which may include a visual identification of the arrhythmogenic region) are saved in the system memory, and a separate ablation catheter may be introduced into the heart and guided to the arrhythmogenic region identified on a visual display of the gated positions of the mapping electrodes.

15 Fig. 35 is a flow diagram illustrating use of the localization system 100 with a linear lesion catheter of the type shown in Figs. 18-26 to treat atrial fibrillation. The steps shown in the flow diagram will be discussed with reference to the illustrations of the heart shown in Figs. 36A - 36C and the examples of the graphical user interface shown in Figs. 31 and 32.

20 First, reference catheters 10, 10a are placed in the coronary sinus and RV apex as illustrated in Figs. 34A and 34B. The reference catheters 10, 10a are preferably represented on the graphical display as shown in Fig. 31. Step 300. Although only the reference transducer positions are precisely known, the catheter locations can be estimated using the transducer positions, the

known spacing of the transducers along the catheter bodies, and a known model of the catheter.

Next, referring to Fig. 36A, marking catheter 12 (Fig. 9) is positioned in the left atrium, preferably by inserting it through a transeptal sheath passed from the right atrium, through the septum and into the left atrium. Steps 302-304. Marking catheter 12 is sequentially positioned with its distal tip at anatomical landmarks, such as the pulmonary veins, septal wall, mitral valve, etc.

The location of each ultrasound transducer 34 on the marking catheter 12 relative to the 3-D coordinate system is calculated using time-of-flight measurements and triangulation. The position of the distal tip is extrapolated from the transducer using a model of the catheter pre-programmed into the system, and is subsequently displayed on the graphical display when the distal tip is positioned at a desired anatomical site (as verified using fluoroscopy), the user adds an appropriate indicator to the display at the distal tip location by entering the necessary input at marker box 156 (Fig. 31). For example, see Fig. 31 in which the left superior pulmonary vein and left inferior pulmonary vein are identified as "LS" and "LI". After the appropriate landmarks are added to the 3-D display, the marking catheter 12 is removed from the heart.

Next, using a mouse or other user input device, lines representing target locations for linear lesions are added to the display. Step 312. These lines are identified by the dashed lines on Fig. 31. The linear lesion catheter 16 (Fig. 8) is next inserted into the left atrium, preferably via the transeptal sheath 87 shown in Fig. 36A. During placement of the linear lesion catheter, the position of ablation window 86 (Fig. 19) is tracked in real time by tracking the positions of the transducers 92 using the localization system 100

PATENT APPLICATION

Express Mailing Label: EM503277091US

and by deriving the window location from the transducer location. An arrow A1 or other icon representing the length of the catheter 16 lying between the transducers 92 is shown on the display as shown in Fig. 31.

5 Referring to Fig. 36B, lesion catheter 16b (shown in Fig. 36B to have an ablation section slidable on a looped baffle wire as described in PCT/US96/17536), is guided using the localization system 100 to a first one of the desired ablation locations marked onto the display by the physician. By manipulating the catheter 16
10 such that the display shows arrow A1 lying over the area marked as a target location, the physician can ensure that the window 86 through which ablation will occur is at the correct location. If a different type of ablation catheter is used, including one which does not involve the use of an electrolytic fluid, the physician may use a
15 similar procedure to align the ablation section (which may be an electrode, an electrode array, or another region of the ablation catheter at which ablation will be carried out) with the target location.

RF energy is supplied to the RF electrodes 90 (Fig. 19) while a
20 conductive fluid is supplied to the fluid port 96 (Fig. 18), to create a linear lesion in the target tissue. Step 318. Arrows A2 or other icons representing the window 86 positions during each ablation are added to the display to indicate the location of a linear lesion. These arrows may be coded by color or other means to indicate
25 characteristics of the lesion, such as the wattage used to create the lesion or the impedance during the ablation. The linear lesion catheter is then repositioned for additional ablation steps until all of the desired ablation locations have been treated.

Next, the linear lesion catheter is removed, and mapping basket 50 is inserted into the left atrium as shown in Fig. 36C. Steps 322, 324. The positions of basket electrodes and arms are determined using the ultrasound localization system and are displayed on the 3-D display in the manner described above. Fig. 32 illustrates the positions of the arms 52 with solid lines and the position of the recording electrodes 56 with stars. Pacing and mapping is carried out using the electrodes 56 in a conventional manner to determine whether the linear lesions have blocked transmission of the electrical currents that traverse the left atrium during an atrial fibrillation episode. The electrical activity measured by the mapping electrodes 56 is shown in the form of an isochronal map over the lesion locations A2 on the three-dimensional display. Steps 328-330. If the linear lesions are found to be successful, the basket catheter is removed and the procedure ended. If additional lesions are necessary, the locating, the ablating, pacing and mapping steps are repeated.

Three-Dimensional Deformable Model

The present invention provides a three-dimensional graphical model of a region of interest within the body (e.g. the heart, abdominal cavity etc.) which may be used together with the visual display generated by the localization system so as to give the physician additional anatomical context as s/he manipulates medical devices within the body. The model is dynamically deformable so that, as information concerning the three-dimensional location of actual physical characteristics in the relevant region is obtained, the model as displayed on the graphical display is changed to more closely resemble the actual region of interest in the patient's body.

PATENT APPLICATION

Express Mailing Label: EM503277091US

The deformable model will be described with reference to the heart, although it is equally suitable for other regions of interest within the body including other organs or cavities.

5 The deformable model system 124a may be programmed into the localization system microprocessor 112 (Fig. 1). Referring to Fig. 37, the system 124a includes a model generation component 125a which generates and displays a "basic" model of a human heart on the graphical display 124 (Fig. 1). The basic model is preferably preprogrammed into the system based on the size and proportions of an average healthy human heart. The model preferably includes basic anatomical features, which for the heart may include four chambers with their associated boundaries, valves, major vessels and their orifices, electro-anatomical structures such as the sinus node, AV node, HIS bundle, ETC., and major anatomical structures such as papillary muscles, chordae, etc.

10 System 124a further includes a transformation component 125b that deforms the model based on input 127a from the localization system concerning the 3-D locations of physical characteristics of the heart and displays the model (as so deformed) on the graphical display 124 (Fig. 1). This input is generated by the localization system using time-of-flight data received from one or more probes positioned within or near the heart. User input 127b, such as an identification of the chamber in which the probe is positioned, is also received by the transformation software and used to deform the model, as described in further detail below.

25 Fig. 38 is a flow diagram illustrating the basic operation of the system. In step 400, a model of the region of interest is provided by the system. Preferably, a model is stored in the system software and used to generate the basic model image on the graphical display.

5 The basic model may be displayed on the graphical display 124 (Fig. 1), or the system may instead delay display of the model until after one or more of the transformations have been carried out. The system may be provided with multiple basic models, each having different characteristics relating to particular classes of patients (e.g. enlarged hearts, hearts having common forms of aneurysms etc.) from which the user can choose for a particular application. The system may further enable the user to add aneurysms, infarct scars, and other conditions to the graphical display of the model by dragging the structures onto the model from a toolbar on the graphical display or by electronically drawing such structures onto the model using a computer mouse.

10 In step 402, the localization system is used together with one or more probes positioned within the heart to obtain information concerning physical characteristics of the heart.

15 If the system is used with the ultrasound localization system described above, each probe includes one or more ultrasound transducers at or near its distal tip. As a probe is manipulated within the heart, the location of its distal tip and thus the location of an adjacent anatomical structure is derived from the location of the transducer using the triangulation algorithm discussed earlier.

20 Although the ultrasound localization system is preferred for use in connection with the deformable model of the invention, the probe may be any kind of probe or medical device that can provide input to the transformation system regarding the physical characteristics of the region of interest.

25 Locations of physical characteristics derived by the localization system are delivered to the transformation software and used in Step 404 to alter the model to more closely conform to the

PATENT APPLICATION

Express Mailing Label: EM503277091US

physical characteristics of the actual heart. A "physical characteristic" can be any feature within the region of interest, ranging from information that a particular x,y,z coordinate is simply part of a space within a chamber, to information that a certain coordinate is an endocardial surface, to more specific information concerning an actual structure such as a valve or vessel. Information of the type obtained using the localization system can be classified into three general categories: anatomical points, interior points, and surface points.

Anatomical points are the three-dimensional positions of specific anatomical structures (or portions thereof) within the heart. These points are highly useful to the transformation software to update the model because they serve to tie down a particular anatomical structure to a particular three dimensional position on the model. To obtain an anatomical point, the user will steer a probe to a known structure using fluoroscopy or other visualization techniques. S/he will then position an identifiable portion of the probe (e.g. the distal tip) at the structure, for example the orifice of the right superior (RS) pulmonary vein. Once the probe is positioned at the known structure, the user provides input identifying the structure at which the probe is positioned using an input device such as a keyboard or mouse. The localization system then determines the three-dimensional location of the anatomical structure and the model transformation software, at Step 404, alters the model so that the RS pulmonary vein on the model coincides with the determined location of that structure in the patient. This anatomical feature will serve as a "hard tack point" for the pulmonary vein, and so further transformations of the model will not move the pulmonary vein from this three-dimensional location.

Additional anatomical point information may be provided to the system by positioning reference catheters such as catheter 10, Fig. 3, at known locations in the region of interest, such as in the coronary sinus ("CS") and right ventricular apex ("RV apex") as described with respect to use of the localization system. Fig. 39A illustrates the way the three-dimensional graphical display might appear if the basic model 600 is displayed after a reference catheter 10 has been placed in the RV apex but before the model has been transformed. It is evident from the visual representation of the catheter 10, which extends beyond the lower walls of the graphical image of the heart, that the model 600 of the heart differs greatly from the actual patient's heart.

Once the catheter 10 is in place, the user enters input into the system indicating that a catheter is positioned in the RV apex. The localization system at step 402 calculates the three-dimensional location of the reference catheter. The transformation software at Step 404 deforms the model so that the RV apex of the model conforms with the actual determined location of the RV apex. The model (as seen in Fig. 39B) is then shown in its deformed state on the graphical display. A similar procedure is preferably also carried out using a coronary sinus catheter. In this manner, the system uses the RV apex and CS catheters to "initialize" the model by defining the gross translation, rotation and scale of the heart and to deform the model to reflect the appropriate translation, rotation and scale.

The second type of information obtained at Step 402, Fig. 38, concerning the physical characteristics of the heart is interior point information. Referring to Fig. 40A, during the procedure the user positions the distal portion of the probe (e.g. catheter 12) within a

chamber of the heart such as the left ventricle. In the example shown in Fig. 40A, the graphical representation of the catheter 12 extends beyond the graphical image of the wall of the left ventricle of the model 600.

5 The user provides input to the transformation system indicating that the probe is within a specified chamber, e.g. the left ventricle. The localization system determines the three-dimensional location of the distal portion of the catheter 12 and provides that information to the transformation system. Once it has been
10 informed the distal portion of the probe is within the specified chamber, the transformation software can use the determined three-dimensional location to further update the model in accordance with Step 404. The model as further updated in this manner is shown in Fig. 40B. It should be noted that while it is useful for the system to
15 receive user input concerning the chamber in which the probe is positioned, this input is not required. The system may determine which chamber the probe is in based on the relative positions of the reference catheters in the RV apex and coronary sinus.

20 Fig. 40C illustrates the transformation undertaken at Step 404 for this particular example. The left ventricular wall of the model prior to transformation is shown in solid lines, and the dashed lines illustrate the transformed state of the model. Arrows illustrate the transformation process.

25 As the probe is steered from place to place within the chamber additional points are gathered and used to update the model. It can thus be seen that the interior point information allows the system to identify multiple points that are known to lie within the specified chamber and to thus approximately conform the size

and shape of the chamber on the model to the size and shape of the corresponding chamber in the patient's heart.

5 A third type of information, surface point information, is obtained by steering the probe into a known chamber of the heart and into contact with the endocardial surface within the chamber. Fig. 41A illustrates the three-dimensional graphical display of the model 600 together with a catheter 12 positioned in contact with the endocardial wall in the left ventricle. Because the model has not yet been deformed to reflect the proper location of the endocardial wall, the catheter is shown as being inside the chamber but spaced from the wall.

10 After confirming that the catheter is in contact with the wall, the user provides input to the system indicating that the catheter is in contact with the wall of a specified chamber. The operator can use a variety of methods to determine whether the probe is in contact with the endocardial surface. One such method involves observing the probe on the fluoroscope (or viewing an un-gated representation of the probe on the localization system display), simultaneously observing the patient's EKG, and determining whether the probe is pulsing with the patient's EKG. The user may also evaluate contact between the probe and the endocardial surface by feeling mechanical resistance as the catheter is advanced. Alternatively, if the probe is provided with mapping electrodes, contact with the endocardial surface may also be confirmed by monitoring EP signals from the mapping electrode(s). Rapid deflection of the EP signals indicates contact between the electrode and the endocardium. The EP signals may be monitored visually on an EP display or automatically by the system as set forth in detail in co-pending Application No. 08/732,511, filed October 15, 1996,

entitled APPARATUS AND METHOD FOR AIDING IN THE
POSITIONING OF A CATHETER. If the monitoring is automatic, the
EP system may automatically send a signal to the transformation
system that the catheter is in contact with the chamber wall.

5 The transformation software receives as input the three-
dimensional locations of points on the endocardial wall which have
been derived by the localization system based on the catheter
position. The model 600 is then deformed as indicated schematically
by arrows in Fig. 41C to bring it into closer conformity with the
10 actual heart. It should be noted that deformations made based on
interior point and surface point information do not change the
positions of the anatomical points ("tack points") that have been
added to the model as described above. The three-dimensional
visual display of the model after transformation is illustrated in Fig.
15 41B.

 Fig. 42 is a flow diagram illustrating a preferred mode of using
the model transformation system. First, at step 500, a model of the
heart is generated and may be shown on the graphical display,
although in the preferred embodiment the model is not visually
20 displayed until after the first transformation has been performed.
Features including disease conditions such as aneurysms, infarct
scars, etc. may be added to the model at any time as described
above.

 At step 502, the user positions ultrasound reference catheters
25 in the coronary sinus and RV apex and provides input to the system
indicating that RV apex and CS catheters have been placed. At step
506 the localization system determines the three-dimensional
locations of the transducers on the CS and RV apex catheters and
provides that information as input to the transformation software.

The transformation software compares the coordinates of the CS and RV apex catheter transducers with corresponding points on the models, and uses that information to scale and orient the model.

Step 506. This transformation step is preferably carried out using the procrustean rigid body transformation techniques as described in I. Borg & J. Lingoes, Multidimensional Similarity, Structure Analysis, Chapter 19 Procrustes Procedures, New York: Springer Verlay, 1987. See Section 19.4. The model as transformed is shown on the graphical display. Step 507.

At step 508, a probe which may be a 7 Fr catheter such as catheter 12, is positioned in the heart, and the user preferably may provide input to the system indicating the general location of the probe. Step 509. For example, the user may indicate which chamber the probe is in. If the probe is placed in contact with the endocardial surface, or at a known anatomical point, that information is preferably input into the system by the user at step 509.

At step 510, the localization system calculates the three-dimensional position of the physical characteristic identified by the probe and delivers that information to the transformation system.

The transformation further deforms the model to incorporate the physical characteristics into the model, preferably using the vector field interpolation method described by D. Ruprecht et al, Spatial Free-Form Deformation With Scattered Data Interpolation Methods, Computers & Graphics, Vol. 1, No. 1, pp. 63-71, 1995, which is incorporated herein by reference. See in particular equations (1) and (2).

Additional physical characteristics are obtained by repositioning the probe(s) and repeating steps 510 and 512 as desired by the user to increase the conformity between the model

and the actual heart. Afterwards, the user may conduct mapping and/or ablation procedures such as those described with respect to Figs. 33 and 35, with the catheters used for those procedures being shown within the deformed model of the heart. The model may be further deformed by following steps 508-516 if the user chooses to do so at any time during the ablation/mapping procedure.

Certain features added to the graphical display during the course of the mapping and/or ablation procedures are added to the endocardial surfaces of the model. For example, maps, including isochronal or isopotential maps, generated during mapping procedures are preferably shown on the endocardial walls of the model appearing on the graphical display. Likewise, lesions formed during the ablation procedure are also shown on the "walls" of the model.

As with the localization system, the user may manipulate the model on the graphical display to rotate or change the orientation of the model. The system also allows the user to take three-dimensional cut-outs through the model across one or more section planes specified by the user using a mouse or other input device. This would result in a three-dimensional section view of the heart and its associated structures.

One embodiment of the system according to the present invention has been described, and it has been described primarily with respect to an ultrasound localization system, EP catheters, and cardiovascular procedures. It should be appreciated, however, that the system and its components may be used in a variety of medical contexts in which three-dimensional representation of structures and surfaces is needed. Thus, the present invention is not to be limited

PATENT APPLICATION

Express Mailing Label: EM503277091US

by the specific embodiments and procedures described herein, but
should be defined only in terms of the following claims.

10/10/2010 10:10:10 AM

Claims

What is claimed is:

1. A method of generating a three-dimensional graphical model of a region located within a living body, comprising the steps of:

(a) generating a three-dimensional model of a region of interest;

(b) determining the three-dimensional location of a physical characteristic in the region of interest using at least one probe positioned within the living body;

(c) deforming the model to at least approximately incorporate the physical characteristic at the determined three-dimensional location; and

(d) displaying the model on a graphical display.

2. The method of claim 1 further including:
repeating steps (b) through (d) multiple times for different probe locations to increase the conformity of the model to the actual region of interest within the living body.

3. The method of claim 1 further including the step of
(e) determining the relative three-dimensional location of a medical device positioned in the region of interest in the living body and graphically representing the medical device superimposed on the model at the determined three-dimensional location.

4. The method of claim 3 wherein the medical device is the at least one probe.

PATENT APPLICATION

Express Mailing Label: EM503277091US

5. The method of claim 3 wherein:
the medical device includes at least one mapping electrode;
step (e) includes determining the relative three-dimensional
location of the at least one mapping electrode; and
5 the method further includes the steps of:
(f) detecting electrical activity using the at least one mapping
electrode; and
(g) generating a map of the detected electrical activity and
superimposing the map on the model at a three-dimensional location
10 corresponding to the determined three-dimensional location of the
electrode.

6. The method of claim 3 wherein:
the medical device includes at least one ablation electrode;
step (e) includes determining the relative three-dimensional
15 location of the at least one ablation electrode; and
the method further includes the steps of:
(f) forming a lesion using the at least one ablation electrode;
and
(g) generating a visual representation of the lesion and
20 superimposing the visual representation on the model at a three-
dimensional location corresponding to the determined three-
dimensional location of the electrode.

7. The method of claim 1 wherein the model generated in
step (a) includes anatomical features known to exist in the actual
25 region of interest, wherein the physical characteristics include
anatomical features, and wherein step (c) includes deforming the
model to correlate at least a portion of the anatomical features on

PATENT APPLICATION

Express Mailing Label: EM503277091US

the model with the determined three-dimensional locations of corresponding anatomical features in the living body.

5 8. The method of claim 7 wherein step (c) includes scaling the model to correlate at least a portion of the anatomical features on the model with the determined three-dimensional locations of corresponding anatomical features in the living body.

10 9. The method of claim 7 wherein step (c) includes orienting the model to correlate at least a portion of the anatomical features of the model with the determined three-dimensional locations of the corresponding anatomical features in the living body.

 10. The method of claim 7 wherein step (c) includes performing a rigid body transformation.

 11. The method of claim 10 wherein the rigid body transformation uses a procrustean algorithm.

15 12. The method of claim 1 wherein step (c) includes performing vector field interpolation on the model.

 13. The method of claim 1 wherein the region of interest is an organ.

 14. The method of claim 13 wherein the organ is a heart.

15. A method of generating a three-dimensional graphical model of an organ located within a living body, comprising the steps of

5 (a) generating a three-dimensional model of at least a portion of an organ, the model including a plurality of anatomical features corresponding to anatomical features in the organ;

(b) obtaining the relative three-dimensional locations of known anatomical features in the organ using a reference probe positioned in the organ;

10 (c) deforming the model using the determined relative three-dimensional locations of the anatomical features in the organ to approximately correlate the three-dimensional locations of the anatomical features on the model to the determined locations of corresponding anatomical features in the organ; and

15 (d) graphically displaying the model.

16. The method of claim 15 further including the steps of:

(e) obtaining the relative three-dimensional location of an additional physical characteristic in the organ using at least one probe positioned in the organ; and

20 (f) further deforming the model to approximately incorporate at least a portion of the additional physical characteristic.

17. The method of claim 16 further including repeating steps (e) and (f) multiple times for different probe locations to increase the conformity of the model to the organ.

PATENT APPLICATION

Express Mailing Label: EM503277091US

18. The method of claim 17 wherein the repeating step includes repositioning the at least one probe multiple times within the organ.

19. The method of claim 15 further including the step of determining the relative three-dimensional location of a medical device positioned in the organ and graphically representing the medical device superimposed on the model at the determined three-dimensional location.

20. The method of claim 19 wherein the medical device is the at least one probe.

21. The method of claim 15 wherein the reference probe includes a plurality of ultrasonic transducers thereon, and wherein: step (b) includes the steps of using ultrasound triangulation techniques to determine the three-dimensional locations of the ultrasonic transducers, and deriving the relative three-dimensional locations of the anatomical features using the relative three-dimensional locations of the ultrasonic transducers.

22. The method of claim 21 further including the steps of:
(e) providing an additional probe having at least one ultrasonic transducer thereon;
(f) positioning the additional probe in the organ;
(g) determining the three-dimensional location of the at least one ultrasonic transducer using ultrasound triangulation techniques;

(h) deriving the relative three-dimensional locations of an additional physical characteristic in the organ using the determined three-dimensional locations of the ultrasonic transducers; and

5 (i) further deforming the model to approximately incorporate at least a portion of the additional physical characteristic.

23. A method of generating a three-dimensional graphical model of a heart located within a living body, comprising the steps of:

10 (a) generating a three-dimensional model of the heart, the model including a plurality of anatomical features corresponding to known anatomical features of hearts;

(b) obtaining the relative three-dimensional locations of known anatomical features in the heart using a reference catheter positioned in the heart;

15 (c) deforming the model using the determined relative three-dimensional locations of the anatomical features in the organ to approximately correlate the three-dimensional locations of the anatomical features on the model to the determined locations of corresponding anatomical features in the heart;

20 (d) positioning an additional probe in a chamber of the heart;

(e) obtaining the relative three-dimensional location of a physical characteristic in the chamber using the additional probe;

(f) further deforming the model to approximately incorporate at least a portion of the physical characteristic; and

25 (g) graphically displaying the model.

PATENT APPLICATION

Express Mailing Label: EM503277091US

24. The method of claim 23 further comprising the step of repositioning the additional probe and repeating steps (e) and (f) multiple times to increase the conformity of the model to the heart.

25. The method of claim 23 further including the steps of:
(h) providing a medical device having at least one electrode;
(i) positioning the medical device in the chamber; and
(j) determining the relative three-dimensional location of the at least one electrode and graphically representing the electrode superimposed on the model at the determined three-dimensional location.

26. The method of claim 25 wherein the medical device is the at least one probe.

27. The method of claim 23 further comprising the steps of:
(h) providing a medical device having at least one mapping electrode;
(i) positioning the medical device in the chamber;
(j) determining the relative three-dimensional location of the at least one mapping electrode
(k) detecting electrical activity using the at least one mapping electrode; and
(l) generating a map of the detected electrical activity and superimposing the map on the model at a three-dimensional location corresponding to the determined three-dimensional location of the electrode.

PATENT APPLICATION

Express Mailing Label: EM503277091US

28. The method of claim 27 wherein the medical device includes a plurality of mapping electrodes, wherein steps (j) through (l) are carried out using the plurality of mapping electrodes, and wherein the map generated in step (l) is an isochronal map.

5 29. The method of claim 27 wherein the medical device includes a plurality of mapping electrodes, wherein steps (j) through (l) are carried out using the plurality of mapping electrodes, and wherein the map generated in step (l) is an isopotential map.

30. The method of claim 23 further including the steps of:
10 (h) providing a medical device having at least one ablation electrode;
(i) positioning the medical device in the chamber;
(j) determining the relative three-dimensional location of the at least one ablation electrode;
15 (k) forming a lesion using the at least one ablation electrode; and
(l) generating a visual representation of the lesion and superimposing the visual representation on the model at a three-dimensional location corresponding to the determined three-dimensional location of the electrode.
20

31. A system for generating a three-dimensional graphical model of a region located within a living body, comprising:
a graphical display;
display software for generating a model of a region of interest
25 and for displaying the model on the graphical display;

PATENT APPLICATION

Express Mailing Label: EM503277091US

a probe positionable with a region in a living body
corresponding to the region of interest;

a localization system for determining the three-dimensional
location of at least a portion of the probe when the probe is
5 positioned in a living body, and for deriving the three-dimensional
location of a physical characteristic in the region of interest from the
determined three-dimensional location of the probe; and

transformation software for deforming the model to at least
approximately incorporate the physical characteristic at the
10 determined three-dimensional location.

32. The system of claim 31 wherein:

the system further includes a medical device positionable in
the region of interest;

the localization system is further for determining the relative
15 three-dimensional location of the medical device when it is
positioned in the region of interest in the living body; and

the display software is further for graphically representing the
medical device superimposed on the model at the determined three-
dimensional location.

20 33. The system of claim 32 wherein:

the medical device includes at least one electrode;

the localization system is further for determining the relative
three-dimensional location of the electrode when it is positioned in
the region of interest in the living body; and

25 the display software is for graphically representing the
electrode superimposed on the model at the determined three-
dimensional location.

34. The system of claim 32 wherein:

the medical device includes at least one mapping electrode;

the localization system is further for determining the relative
three-dimensional location of the mapping electrode when it is
positioned in the region of interest in the living body;

the system further includes an electrophysiology system for
receiving detected electrical activity from the mapping electrode and
for generating a map of the electrical activity; and

the display software is for graphically representing the map
superimposed on the model at the three-dimensional location
corresponding to the three-dimensional location of the electrode.

35. The system of claim 32 wherein:

the medical device includes at least one ablation electrode;

the localization system is further for determining the relative
three-dimensional location of the ablation electrode when it is
positioned in the region of interest in the living body;

the system further includes an ablation system for delivering
ablation energy to the ablation electrode; and

the display software is for generating a visual representation
of an ablation lesion and for superimposing the visual representation
of the lesion on the model at a three-dimensional location
corresponding to the three-dimensional location of the electrode.

36. The system of claim 31 wherein the display software is
for generating and displaying a model of an organ.

37. The system of claim 36 wherein the organ is a heart.

38. A system for generating a three-dimensional graphical model of an organ located within a living body, comprising:

a graphical display;

display software for generating a model of an organ and for displaying the model on the graphical display, the model including a plurality of anatomical features corresponding to anatomical features in the organ;

a reference probe positionable within or in proximity to an organ in a living body;

a localization system for determining the three-dimensional location of at least a portion of the reference probe when the probe is positioned within or in proximity to the organ, and for deriving the three-dimensional locations of anatomical features in the organ from the determined three-dimensional location of the reference probe;

and

transformation software for deforming the model to at least approximately correlate the three-dimensional locations of the anatomical features on the model to the determined locations of corresponding anatomical features in the organ.

39. The system of claim 38 wherein:

the system further comprises an additional probe positionable within or in proximity to the organ;

the localization system is further for obtaining the relative three-dimensional location of at least a portion of the additional probe and for deriving the three-dimensional location of an additional physical characteristic of the organ from the three-dimensional location of the additional probe; and

PATENT APPLICATION

Express Mailing Label: EM503277091US

the transformation software is further for deforming the model to approximately incorporate at least a portion of the additional physical characteristic.

40. The system of claim 39 wherein:

the probe is moveable to multiple locations within the organ; the localization system is further for deriving the locations of multiple physical characteristics within the organ from each of the multiple locations of the additional probe; and

the transformation software is further for deforming the model to approximately incorporate the multiple physical characteristics to increase the conformity between the model and the organ.

41. The system of claim 38 wherein the organ is a heart.

42. The system of claim 41 wherein:

the system further includes a medical device positionable in the heart;

the localization system is further for determining the relative three-dimensional location of the medical device when it is positioned in the heart; and

the display software is further for graphically representing at least a portion the medical device superimposed on the model at the determined three-dimensional location.

43. The system of claim 42 wherein:

the medical device includes at least one electrode;

the localization system is further for determining the relative three-dimensional location of the at least one electrode when it is positioned in the heart; and

5 the display software is for graphically representing the electrode superimposed on the model at the determined three-dimensional location.

44. The system of claim 42 wherein
the medical device includes at least one mapping electrode;
the localization system is further for determining the relative
10 three-dimensional location of the at least one mapping electrode when it is positioned in the heart;

the system further includes an electrophysiology system for receiving detected electrical activity from the mapping electrode and for generating a map of electrical activity within the heart; and
15 the display software is further for superimposing the map on the model at a three-dimensional location corresponding to the three-dimensional location of the electrode.

45. The system of claim 42 wherein:
the medical device includes at least one ablation electrode;
20 the localization system is further for determining the relative three-dimensional location of the at least one ablation electrode when it is positioned in the heart;

the system further includes an ablation system for delivering ablation energy to the ablation electrode to create a lesion in the
25 heart; and

the display software is further for generating a visual representation of an ablation lesion and for superimposing the visual

representation on the model at a three-dimensional location corresponding to the three-dimensional location of the electrode.

5 46. The system of claim 44 wherein the medical device includes a plurality of mapping electrodes, wherein the electrophysiology system is for generating an isochronal map, and wherein the display software is for superimposing the map on the model.

10 47. The system of claim 44 wherein the medical device includes a plurality of mapping electrodes, wherein the electrophysiology system is for generating an isopotential map, and wherein the display software is for superimposing the map on the model.

15 48. A method of graphically displaying and dynamically correcting an image of organ comprising the steps of:
 generating a graphical image of the organ;
 inserting a catheter into the body and obtaining data corresponding to the location of a physical characteristic associated with the organ;
 modifying the graphical image with the location data;
20 and
 displaying the modified graphical image.

 49. A method as recited in claim 48 wherein the physical characteristic is an anatomical feature.

50. A method as recited in claim 48 wherein the physical characteristic is an interior point.

51. A method as recited in claim 48 wherein the physical characteristic is an interior point.

5 52. A method as recited in claim 48 further include the step of repositioning the catheter multiple times and repeating the obtaining, modifying and displaying steps for each catheter position.

53. A method as recited in claim 48 further including the step of obtaining a fluoroscopic image of the catheter and its position with respect to the organ and modifying the graphical image with the fluoroscopic position information.

54. A method as recited in claim 48 further including the step of obtaining input specifying the physical characteristic associated with the organ and modifying the graphical image with the input.

55. A method as recited in claim 48 wherein the method further comprises the steps of positioning a plurality of ultrasonic transducers into the body, at least one of the ultrasonic transducers being on the catheter, and wherein the obtaining step includes the steps of:

causing the transducers to generate and/or receive ultrasound signals and recording the elapsed time between the generation of signals from each transmitting one of the

transducers and the receipt of the signals by receiving ones of the transducers;

determining the three-dimensional location of the catheter based on the recorded times; and

5 deriving the location of the physical characteristic from the determined location of the catheter.

56. A system for graphically displaying and dynamically correcting an image of organ comprising:

10 a processor for generating an image of an organ;
a display for displaying the generated image;
a catheter for placement into the body adjacent the organ; and

15 means associated with the catheter for generating data related to the position of the catheter and wherein said processor utilizes said position data to update the image of the organ.

20 57. A system as recited in claim 56 further including means for obtaining a fluoroscopic image of the organ and the catheter further including a means for inputting information related to the location of the catheter obtained from the fluoroscopic image into the processor to further update the image of the organ.

25 58. A system as recited in claim 56 wherein the system further includes a plurality of ultrasonic transducers positionable within the living body, at least one of the transducers being on the catheter, and wherein the means associated with the catheter includes:

PATENT APPLICATION

Express Mailing Label: EM503277091US

localization hardware electronically coupled to the transducers
for causing the ultrasound transducers to transmit and/or receive
ultrasound signals and for measuring the elapsed time between
transmission of ultrasound signals by transmitting transducers and
5 receipt of the signals by receiving transducers;

processor means electronically coupled to the localization
hardware for calculating the distances between the transducers
using the measured elapsed time, for determining the three-
dimensional location of the catheter, and for deriving the location of
10 the organ from the three dimensional location of the catheter.

PATENT APPLICATION

Express Mailing Label: EM503277091US

ABSTRACT OF THE DISCLOSURE

The present invention is a system and method for graphically displaying a three-dimensional model of a region located within a living body. A three-dimensional model of a region of interest is displayed on a graphical display. The location in three-dimensional space of a physical characteristic (e.g. a structure, wall or space) in the region of interest is determined using at least one probe positioned within the living body. The graphical display of the model is deformed to approximately reflect the determined three-dimensional location of the physical characteristic. Preferably, the probe or probes are moved throughout the region of interest so as to gather multiple data points that can be used to increase the conformity between the graphical display and the actual region of interest within the patient.




Fig. 1

A 3D coordinate system with axes x , y , and z . A shaded tetrahedron is shown in the first octant. The vertices are labeled T_{REF1} (at the origin), T_{REF2} (on the x -axis), T_{REF3} (on the yz -plane), and T_{REF4} (in the interior). A point T_{CATH} is shown outside the tetrahedron. Distances d_1 through d_6 are marked along the edges and from vertices to the opposite faces. Handwritten notes specify constraints: T_{REF1} is constrained to be at the origin, T_{REF2} is constrained to be on the x -axis, T_{REF3} is constrained to be in the plane $z=0$, and T_{REF4} is constrained to be in the half space $z>0$.

Fig. 2






Fig. 3






FIGURE 6 PIEZOELECTRIC CYLINDER




FIGURE 7. TRANSDUCER WITH LENS




FIGURE 8 POLYMER PIEZOELECTRIC
WRAPPED AROUND
MANDREL




Fig. 9

PIEZOELECTRIC TRANSDUCER 34







FIGURE 10 DISTAL TRANSDUCER ON ABLATION CATHETER






FIG. 18




FIG. 23




FIG. 24




Fig. 25










Fig. 26

FIG 27A










Fig 29



FIG. 30A




FIG. 30 B

3D User Interface





Figure 31



Clinical Method for Ventricular Tachycardia

Using 3D Basket with Integrated Ablation

Device Interaction

Software Interaction




FIG. 33

00128304.000395




FIG. 3A

A hand-drawn schematic diagram of a heart, showing the right ventricle (RV) and left ventricle (LV). The RV is on the left, and the LV is on the right. A catheter is inserted into the RV, with four electrodes labeled 1, 2, 3, and 4. Another catheter is inserted into the LV, with eight electrodes labeled 5 through 12. Arrows indicate the direction of catheter insertion.

FIG 34C

09128304.080398




FIG 34B

Clinical Method for Atrial Fibrillation




FIG. 35




Figure 36A

86E080" 40E2160




Figure 36b

SECRETED 10/22/2000




Figure 36C




FIG. 37






FIG. 38






Fig 40A




Fig 40B




FIG. 40C




Fig 41B




Fig 41A

09130304.080393





Figure 41C



DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A DYNAMICALLY ALTERABLE THREE-DIMENSIONAL GRAPHICAL MODEL OF A BODY REGION

the specification of which (check one) X is attached hereto or ___ was filed on ___ as Application No. ___ and was amended on ___ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed
Yes _____ No _____

Number	Country	Day/Month/Year Filed
--------	---------	----------------------

Number	Country	Day/Month/Year Filed
--------	---------	----------------------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) below.

Application Number	Filing Date
--------------------	-------------

Application Number

Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Filing Date	Status: Patented, Pending, Abandoned
--------------------	-------------	--------------------------------------

Application Number	Filing Date	Status: Patented, Pending, Abandoned
--------------------	-------------	--------------------------------------

Full name of sole or first inventor N. PARKER WILLIS

Residence 98 Reservoir Road, Atherton, CA 94027
Citizenship USA

Full name of second joint inventor, if any, JINGLIN ZENG

Residence 1532 Chihong Drive, San Jose, CA 95131
Citizenship Peoples Republic of China

Full name of third joint inventor, if any, JAMES A. QUARATO

Residence 1381 Sidney Drive, Sunnyvale, CA 94087
Citizenship USA

Full name of fourth joint inventor, if any, _____

Inventor's signature _____ Date _____

Residence _____
Citizenship _____

Post Office Address _____

Attorney Docket No. CRDP-2700IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION FOR UNITED STATES PATENT

In re Patent Application of)
)
N. PARKER WILLIS et al.)
)
Appln. No. New)
)
Filed: August 3, 1998)
)
For: **A DYNAMICALLY ALTERABLE THREE-
DIMENSIONAL GRAPHICAL MODEL OF A
BODY REGION**)
)

Group Art Unit:

**POWER OF ATTORNEY BY ASSIGNEE AND CERTIFICATE
BY ASSIGNEE UNDER 37 CFR § 3.73(b)**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Cardiac Pathways Corporation, assignee of the entire right title and interest in the above-identified application by assignment dated 7/31/98, which assignment is ☐ recorded in the Patent and Trademark Office at Reel , frame , ☒ attached hereto, hereby appoints the members of the firm of LIMBACH & LIMBACH L.L.P., a firm composed of:

Karl A. Limbach	18,689	W. Patrick Bengtsson	32,456	Kyla L. Harriel	P-41,816
George C. Limbach	19,305	Mark A. Dalla Valle	34,147	Mayumi Maeda	40,075
John K. Uilkema	20,282	Charles P. Sammut	28,901	Kent J. Tobin	39,496
Neil A. Smith	25,441	Mark C. Pickering	36,239	Christine S. Ring	P-42,106
Veronica C. Devitt	29,375	Kathleen A. Frost	37,326	Michael R. Ward	38,651
Ronald L. Yin	27,607	Alan S. Hodes	38,185	Steven M. Santisi	40,157
Gerald T. Sekimura	30,103	Patricia Coleman James	37,155	Charles L. Hamilton	P-42,624
Michael A. Stallman	29,444	Alan A. Limbach	39,749	Andrew V. Smith	P-43,132
Philip A. Girard	28,848	Douglas C. Limbach	35,249	Heath W. Hoglund	41,076
Michael J. Pollock	29,098	Brian J. Keating	39,520	J. Thomas McCarthy	22,420
Stephen M. Everett	30,050	Seong-Kun Oh*			
Alfred A. Equitz	30,922	Cameron A. King	P-41,897		

* Recognition under 37 CFR 10.9(b)

as its attorneys with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

The assignee certifies that it has reviewed the assignment and to the best of the assignee's knowledge and belief, title is in the assignee.

Please direct all correspondence regarding this application to the following:

LIMBACH & LIMBACH L.L.P.
Attn: Kathleen A. Frost
2001 Ferry Building
San Francisco, CA 94111

Telephone: (415) 433-4150
Facsimile: (415) 433-8716

Dated: 7/31/98

Cardiac Pathways Corporation

By:

Name: David W. Gryski Richard Riley
Title: Vice Pres. Finance and CFO Exec. Vice President, R&D

Applicant or Patentee: N. PARKER WILLIS et al.

Attorney's

Appln. or Patent No.: NewDocket No.: CRDP-2700Filed or Issued: August 3, 1998For: A DYNAMICALLY ALTERABLE THREE-DIMENSIONAL GRAPHICAL MODEL OF A BODY REGION**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

☐ the owner of the small business concern identified below:☒ an official of the small business concern empowered to act on behalf of the concern identified below:NAME OF CONCERN Cardiac Pathways CorporationADDRESS OF CONCERN 995 Benecia Avenue, Sunnyvale, CA 94086

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled **A DYNAMICALLY ALTERABLE THREE-DIMENSIONAL GRAPHICAL MODEL OF A BODY REGION** by inventor(s) N. PARKER WILLIS described in

☒ the specification filed herewith with title as listed above.☐ application no. , filed .☐ patent no. , issued .

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME _____

ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

NAME _____

ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time or paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING David W. Gryzka RICHARD RILEYTITLE OF PERSON OTHER THAN OWNER Vice Pres. Finance and CFO Executive Vice President, R&DADDRESS OF PERSON SIGNING 995 Benecia Avenue, Sunnyvale, CA 94086SIGNATURE: Richard RileyDATE: 7/31/98